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ABSTRACT
THE EFFECTS OF POST-OPERATIVE ANALGESICS ON OVARIAN SURFACE
ANGIOGENESIS AFTER TRANSPLANTATION OF YOUNG OVARIES INTO
AGED MICE
by Christine A. Petrovec
The formation of new blood vessels from pre-existing vasculature, termed
angiogenesis, is essential for tissue viability and continuous organ function after murine
ovary allotransplantation. Interference with the process of angiogenesis can result in
cellular injury and tissue necrosis in the transplanted ovarian tissue. Although
recommended, the use of analgesics for post-operative pain management has been shown
to alter angiogenesis and could negatively affect transplanted ovarian tissue viability.
The present study evaluated the effects of two analgesics, the opiate buprenorphine and
the non-steroidal anti-inflammatory drug meloxicam, on superficial ovarian vessel
formation after the transplantation of young ovaries into aged mice. One-Way ANOVA
evaluation indicated a significant increase in total surface vessel number (p= 0.001) and
total number of vessel branches (p= 0.027) in meloxicam-treated mice when compared to
the saline control or buprenorphine-treated mice. Additionally, the meloxicam-treated
mice showed a significantly greater concentration of vessels at an ovary surface depth of
approximately 90 µm (p< 0.001) when compared to both saline control and
buprenorphine-treated mice. These results suggest that meloxicam is a post-operative
analgesic that could be used after ovary allotransplantation to limit disruptions in
angiogenesis and to maximize vessel formation to establish successful ovary function.
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Introduction

In order to immediately preserve tissue viability in modern organ transplantation
the anastomosis of larger vessels is required for successful vascular perfusion leading to
consistent gas and nutrient distribution and swift metabolic waste removal (Brodie, 1903;
Starzi, 1960; von Frey, 1885). Although highly effective suture techniques used to
connect major vessels were originally perfected by 1912 Nobel Prize winner Alexis
Carrel (Carrel, 1905; Carrel, 1907), using similar methods to exogenously conjoin smaller
vessels of the microvasculature intra-operatively proved to be an impracticable and
unsuccessful way of creating microvascular patency (Acland, 1977; Baxter, 1972; Brooks,
1959). Therefore, regrowth and remodeling of the microvasculature in areas of cellular
hypoxia is primarily the work of endogenous cell signaling that results in the emergence
of new vasculature from pre-existing vessels, a biological phenomenon termed
angiogenesis (Ladoux, 1993; Shweiki, 1992; Stone, 1995).

Angiogenesis
First described by British surgeon John Hunter in 1787 to characterize new vessel
growth from the pre-existing microcirculation after ligation of the carotid artery perfusing
a reindeer antler (Kobler, 1960), angiogenesis did not become common terminology until
revisited by Arthur Hertig when he described vessel formation in the placenta of pregnant
monkeys (Hertig, 1918). As a well known, essential biological event in both normal
physiological and divergent pathological processes, the mechanisms of angiogenesis
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continue to be investigated to understand the pathways and components involved in the
formation of new vessels and vascular regeneration.
The process of angiogenesis usually takes place in the microvasculature,
predominantly in capillaries, but it can also be observed in small venules (Schoefl, 1963).
The basic structure of nascent capillary parent vessels consist of a single layer of
endothelial cells surrounded by a thin extracellular matrix (ECM) with structurally
supportive pericytes wrapped around individual endothelial cells and embedded in the
ECM to propagate external signals through cell-cell gap junctions (Bar, 1972; Cuevas,
1984; Florey, 1926; Orlidge, 1987). In addition, the ECM is comprised of proteoglycans,
Type I collagen, and elastin that provide additional support for the delicate
microvasculature (Form, 1986; Kubota, 1988; Lohler, 1984; Sauter, 1998).
When angiogenic stimulators such as vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF) are released via proteolysis of the ECM, both
VEGF and bFGF bind specific endothelial cell transmembrane receptors activating
mitogenesis (Connolly, 1989; Ferrara, 1989; Fisher, 1994; Folkman, 1988; Healy, 1992;
Hiraoka, 1998; Jakeman, 1992; Montesano, 1986; Unemori, 1992). These endothelial
transmembrane tyrosine kinase receptors, such as VEGF binding VEGFR-2/flk-1 and
VEGFR-1/flt-1, and bFGF binding FGFR1/2, become phosphorylated and activate
phospholipase-C. Activated phospholipase-C subsequently stimulates the mitogenactivated protein (MAP) kinase extracellular signal-regulated kinases (ERK) 1/2 signal
transduction pathway by phosphorylation of its G-protein coupled receptor alpha subunit
(Lee, 1989; Takahashi, 1997; Yamane, 1994). After phosphorylation, the alpha subunit
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signals the activation of Ras, which eventually activates MAP kinase transcription factors
Myc and cAMP response-element binding protein (CREB) to translocate into the
endothelial cell nucleus leading to increased mitogenesis, vascular fenestration, and
increased permeability (Berra, 2000; Connolly, 1989; Pearson, 2001; Senger, 1983;
Unemori, 1992). These vascular changes are necessary to release extracellular matrix
proteolytic enzymes, such as matrix metalloproteinases, which remodel existing ECM
structures, and facilitate the secretion of newly assembled ECM components after cellular
proliferation forms the beginning of a new microvessel (Fernandez, 1999; Pepper, 1998).
As parent endothelial cells are rapidly multiplying, angiogenic growth factors
angiopoietin-1 (ang-1) and angiopoietin-2 (ang-2) are released from the damaged
extracellular matrix and bind to endothelial cell surface tie-1and tie-2 tyrosine kinase
receptors (Maisonpierre, 1997; Puri, 1995; Sato, 1995; Suri, 1996; Thurston, 1999).
Specifically, the ang-1 ligand binds to the endothelial cell tie-2 receptor leading to
receptor phosphorylation. This binding prevents excessive vessel leakage due to
fenestrations caused by the degradation of cell-cell interaction molecules PECAM/CD31
and VE-cadherin. Limiting vessel permeability allows the vessel to retain adequate
structural integrity during the proliferative process (Puri, 1995; Thurston, 1999). Ang-2
activates the endothelial tie-2 receptor to induce the release of pericytes from the
basement membrane (Sato, 1995). This disruption of pericyte attachment is expedited by
the dissolution of the extracellular matrix by endothelial cell secreted proteolytic
enzymes on the side of the vessel closest to the angiogenic stimulus (Ausprunk, 1977;
Korff, 2001; Maisonpierre, 1997; Papapetropoulos, 1999). At this juncture, ang-2
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stimulation of the endothelial tie-2 receptor acts concomitantly with VEGF to facilitate
endothelial cell sprouting from the area of degraded ECM (Asahara, 1998; Sawamiphak,
2010; Witzenbichler, 1998).
The degraded area of ECM is invaded by proliferating endothelial cells forming
a sprout, with a small number of apical cells leading the bulk of new cells in a linear
progression. Those cells that follow behind or to the sides of the apical cells are referred
to as stalk cells, which divide and elongate as the stalk moves forward (Witzenbichler,
1998). Simultaneously, the sprout interacts with the remodeled ECM as new basement
membrane components such as fibronectin, collagen, and laminin are secreted through
the parent vessel fenestrations and deposited while maintaining contact with the
proliferating endothelial cells (Saunders, 2006; Stratman, 2009).
As the sprout matures, endothelial cellular polarity is maintained due to ang-1/tie1 receptor signaling (Asahara, 1998). The new lumen is constructed when endothelial
cells form VE-cadherin/VEGF mediated intercellular adhesions and secreted protease
inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) stop the degradation of
the ECM, allowing new ECM components to assemble (Form, 1986; Saunders, 2006).
As soon as sufficient basement membrane is deposited and endothelial junctions are
established, pericytes synthesized after VEGF-stimulation are recruited to position
themselves around the new capillary endothelial cells, signifying the maturation of the
vessel wall (Stratman, 2009; Yamagishi, 1999). Upon the loop formation from the
coalescence of two sprouts or with another vessel branch, blood flow is initiated into the
newly formed microvessel. Once the new vessel is patent, the incorporated endothelial

4	
  	
  

	
  

cells will become dormant for months to years. These quiescent endothelial cells and the
surrounding pericytes in the vascular network suppress proliferation unless signaled again
by stimulatory mitogens such as VEGF and bFGF (Montesano, 1986; Unemori, 1992).

Murine Ovary
Re-establishing an adequate angiogenic pathway after surgeries such as murine
ovarian allotransplantation allows for the continued maturation and development of
primordial follicles into mature follicles and the maintenance of estrus cyclicity (Gosden,
1994). Studies investigating neovascularization after human ovarian xenografts
demonstrated a rapid rate of angiogenesis in transplanted ovarian tissue resulting in
complete vascular perfusion at the graft-host interface within 48 hours (Nisolle, 2000;
Van Eyck, 2010). This is most likely due to the ongoing presence of VEGF and bFGF
angiogenic factors responsible for vessel formation during folliculogenesis and
development of the corpus luteum during the luteal phase (Boron & Boulpaep, 2008;
Dissen, 1994; Ferrara, 1998; Li 1994). In mice, the ovaries are enclosed in an ovarian
bursa which includes an inner mesothelium lining composed of blood vessels and nerves
(Treuting & Dintzis, 2011). The ovarian artery, ovarian vein, and major nerves join the
ovary at the narrow opening called the hilum and enter and leave through a small hole in
the bursa lining. The ovarian bursa is continuous with the murine oviducts which
connect to the uterine horns of a bicornuate uterus (Treuting & Dintzis, 2011).
In the ovary, the process of folliculogenesis describes the maturation of
primordial follicles to preovulatory follicles in response to gonadotropin releasing
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hormone (GnRH) released from the hypothalamus as well as follicle-stimulating hormone
(FSH) and lutenizing hormone (LH) released from the anterior pituitary gland (Boron &
Boulpaep, 2008). Proliferation of follicular granulosa cells and the surrounding theca cell
layers continue in response to LH and FSH as the follicle develops. As follicles advance
from the primary follicle stage through the tertiary stage, increasing nutritional demands
stimulate endogenous secretion of VEGF and bFGF from the bursa, ovarian endothelial
cells, and granulosa cells to increase vascularization surrounding the developing follicle
(Bassett, 1943; Doyle, 2009; Mattioli, 2001; Nilsson, 2001; Zheng, 1994). It has been
hypothesized that the introduction of a murine ovary homograft will be met with rapid
angiogenesis due to an already large production of VEGF and bFGF from bursa
endothelial, thecal, and granulosa cell origins in addition to the increased production
stimulated from cellular hypoxia (Kamat, 1995; Koos, 1991; Van Eyck, 2010; Zheng,
1994). Studies have also indicated that tie-1 and tie-2 receptors are present on ovary
endothelial cells and bind vascular growth factors ang-1 and ang-2 released from bursa
mesodermal cells in response to increased VEGF signaling promoting post-operative
angiogenesis (Teilmann, 2005). It has also been hypothesized that during the avascular
period of local ischemia in the host bursa after ovary transplantation the increased VEGF
signaling stimulates both local angiogenesis and the release of bone marrow derived
endothelial progenitor cells necessary for postnatal vasculogenesis (Asahara, 1999;
Roberts, 2007).
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Vasculogenesis
Vasculogenesis refers to the formation of nascent vascular structures de novo and
is traditionally used to describe new vessel formation in the developing embryo. After
the early mesodermal layer is formed via gastrulation (Tam, 1997), mitogens from the
fibroblast growth factor (FGF) family stimulate mesodermal stem cells to differentiate
into an early hematopoietic precursor, the hemangioblast (Amaya, 1991; Choi, 1998;
Coumoul, 2003; Flamme, 1992; Gospodarowicz, 1974; Wilt, 1965). These VEGFR2/flk-1 positive hemangioblasts migrate toward high concentrations of mitogen VEGF,
often traveling long distances to specific tissue locations to begin forming a primordial
vascular plexus (Drake, 1995; Schuch, 2003; Shalaby, 1995; Shalaby, 1997). After
stimulation by VEGF, the hemangioblast proliferates and differentiates into endothelial
progenitor cells, or angioblasts, and hematopoietic stem cells (Breier, 1995; Ferrara,
1996; Leung, 1989; Millauer, 1993). Once these cells have reached their extraembryonic
destination, the hematopoietic stem cells and angioblasts aggregate to form ‘blood
islands’, with the hematopoietic stem cells in the lumen, surrounded by a fused layer of
angioblasts at the periphery (Drake, 2000; Risau, 1988). To form nascent vessel lumina,
neighboring blood islands coalesce and the angioblasts merge, differentiating into
embryonic endothelial cells with downregulated VEGFR2/flk-1 receptors and
upregulated growth factor receptors. These growth factor receptors include CD34 and
CD31 prolific angiogenic factors and VE-cadherin, E-selectin extracellular matrix and
cell-cell adhesion factors (Doetschman, 1985; Hirakow, 1981). Eventually, the newly
established endothelial cells will generate stable cell-cell interactions using CD31 and
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VE-cadherin, and recruit pericytes to stabilize the vessel and stimulate the generation of
extracellular matrix components (Bar, 1972).
In vasculogenesis of the ovary, the primitive gonad is formed from the migration
of primordial germ cells to the mesothelial layer of the mesoderm and the endothelial
cells that line this layer connect these germ cells to the vascular plexus of the primitive
microcirculation (Bullejos 2002; Coveney, 2008). More complex ovary vascular
structures develop by continued endothelial cell proliferation and branching of these early
endothelial vessel formations extending from the larger vascular plexus of the
mesonephros (Bullejos 2002; Coveney, 2008). After the female gonad becomes fully
vascularized via further vessel reorganization and migration, PECAM-1/CD31 cell-cell
adhesions and characteristic angiogenic microvessel branching indicate the end of
vasculogenesis (Coveney, 2008; DeLisser, 1997; Horace, 1997).
Recent studies have detected quiescent undifferentiated endothelial progenitor
cells similar to early embryonic progenitor cells in the bone marrow and peripheral blood
of adult humans (Asahara, 1997; Asahara, 1999; Jin, 2006; Vaughan, 2012). Referred to
as angioblasts in the developing embryo, these newly-identified adult circulating
endothelial progenitor cells (EPCs) can be summoned and up-regulated in adults by
ischemia, cytokines, and growth factors such as VEGF. Once in circulation, EPCs
contribute to the production of new vessels in areas of decreasing oxygen tension,
elevated blood viscosity or excessive luminal pressure. Research has shown that many of
these quiescent EPCs reside in the bone marrow without need for proliferation, and
modest amounts are available in circulation to assist in the formation of new capillary
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networks (Asahara, 1999). The bone marrow derived endothelial progenitor cells (BMEPCs) that can be mobilized by mitotic VEGF activation are directed in a chemotaxic
manner towards large secretions of VEGF (Jin, 2006). In the mature murine ovary,
VEGF is necessary for the formation of the corpus luteum (Ferrara, 1998) and subsequent
studies have identified BM-EPCs in the vascularization process during luteal formation
and neovascularization in the endometrium (Asahara, 1999). After localization to
reproductive tissues, it is hypothesized that BM-EPCs can replicate embryonic pathways
of vessel creation to assist with the formation of new capillary beds in areas of vascular
injury, such as murine ovary allotransplantation into a host bursa, increasing regional
perfusion, and restoring tissue function (Asahara, 1999).

Post-operative analgesia
Any alteration to angiogenesis, vasculogenesis or the release of BM-EPCs could
alter the host’s ability to maintain transplanted tissue viability by prolonging wound
healing or sufficient organ perfusion. Although many post-operative precautions are
taken to ensure the host’s comfort, post-operative analgesia has been shown to cause
significant reduction in immunosuppressive stress hormone secretion from hypothalamicpituitary axis activation thus resulting in adequate secretion of proinflammatory cytokines
required for wound repair (Beilin, 2003; Glaser, 1999; Hubner, 1996; Padgett, 1998;
Skjelbred, 1982). It has been demonstrated in various species that providing patients
with analgesia after both major and minor procedures is beneficial, and in rodents such as
mice, post-operative analgesia decreases the risk of sepsis, stimulates healthy immune
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function, increases animal mobility, and decreases stress-induced delays in wound
healing (Hubner, 1996; Padgett, 1998).
The current recommendation given by Institutional Animal Care and Use
Committees (IACUC) as well as veterinary medical practitioners is to provide adequate
post-operative pain management for laboratory animals undergoing surgical procedures
(Kohn, 2007). In an effort to comply with these reasonable guidelines but still maintain
reliable research results in studies evaluating surgical transplantation procedures such as
the murine ovarian homograft, multiple genres of available analgesia should be evaluated
for possible effects on post-operative angiogenesis and vasculogenesis. Currently, the
most widely used post-operative analgesics are from either the opioid class or nonsteroidal anti-inflammatory drugs (NSAIDs). Evaluating which of these two types of
analgesia will have the least negative effect on angiogenic factors or vasculogenesis
endothelial progenitor signaling could be determined by looking at the mechanism of
action and reviewing previous literature for evidence of enhanced or inhibited postoperative transplant neovascularization.

Buprenorphine
The most common opioid used ubiquitously in both human and animal studies,
buprenorphine hydrochloride, is a semi-synthetic µ-opioid partial agonist used for the
relief of moderate to severe pain (Cowan, 1977). In 1966 John Lewis, lead chemist of the
pharmaceutical division of United Kingdom consumer goods company Reckitt & Colman
(currently Reckitt Benckiser) in conjunction with chemist Kenneth Bentley, formulated a
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potent novel analgesic by adding a C-7 side-chain containing a t-butyl group to opiate
alkaloid thebaine (Bentley, 1967). Injectable buprenorphine became commercially
available in 1978 as an alternative analgesic for severe pain. By 1985, both injectable
and sublingual tablets were approved by the FDA and available in the United States.
Currently, the Food and Drug administration lists buprenorphine as a schedule III
narcotic (DEA, 2002).
Approved for intraperitoneal (IP), intravenous (IV), oral, and intramuscular
administration, buprenorphine has a high affinity for central nervous system G-protein
coupled µ-opioid receptor subclasses, and it demonstrates a prolonged receptor
disassociation rate, which generates low buprenorphine plasma concentrations leading to
extended analgesic effects (Boas, 1985; Cowan, 1977; Huang, 2001; Sadee, 1982; Yassen,
2007). After binding to the µ-opioid receptor, buprenorphine disinhibits the presynaptic
release of GABA leading to analgesia, sedation, bradypnea, hypotension, and dysphoria
(Gal, 1989; North, 1987; Saarialho-Kere, 1987; Vaughn, 1997). Subsequent disruption of
G-protein coupled receptor (GPCR) signaling requires inactivation of the G-protein alpha
subunit by stimulating GTP hydrolysis rendering the subunit inactive by regulators of Gprotein signaling (RGSs) and/or desensitization by binding of Arrestin proteins which
eliminates further signal transduction by blocking the buprenorphine binding site
(Ferguson, 1996; Zhang, 1998).
After thoroughly analyzing all routes of buprenorphine administration,
researchers demonstrated that the sublingual and IV routes had the longest half-life at 3-5
hours and the most rapid post-administration bioavailability. Although convenient,
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studies revealed the sublingual application required a higher dose due to an increased
hepatic first-pass effect (Brewster, 1981; Bullingham, 1980; Kuhlman, 1996). With a
hepatic elimination rate of approximately 40 hours, buprenorphine is deactivated via Ndealkylation by Cytochrome P450-3A4 enzymes in the liver and the resulting metabolite
norbuprenorphine is then bound to a glucuronic acid and excreted in feces via bile
(Iribarne, 1997; Zhang, 2003).
As one of the most common post-operative analgesics used in medicine today,
buprenorphine’s parent alkaloid morphine has been analyzed in numerous studies
investigating the pro-angiogenic or inhibitory effects of opioids on wound healing and
transplant neovascularization. By using morphine instead of buprenorphine specifically,
research studies can evaluate the effects of all opioid plant alkaloid derivatives which
include thebaine, codeine, and buprenorphine. In early studies by Pasi et al (1991) the
chorioallantoic membrane (CAM) of the chicken embryo was used to evaluate the effects
of morphine on angiogenesis. By displaying the CAM through shell fenestrations after
the third incubation day, Pasi et al inoculated the eggs with control (saline) or morphine
in varying doses and counted daily vessel growth. Since Zagon and Mclaughlin (1981)
had suggested in earlier research that opioid therapy resulted in the inhibition of murine
tumor growth, Pasi et al hypothesized that the inhibitory mechanisms of these opioids on
the developing membrane may be due to decreased endothelial cell proliferation leading
to slower vessel formation. Pasi et al found morphine treated CAM had decreased
neovascularization in a dose dependent manner with the negative effects of morphine
easily visible at low doses (5 µg) within the first 24 hours, and high-dose morphine (10
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µg and 15 µg) maintaining significant angiostatic effects over the 96-hour observation
period. These results suggested that opioids might inhibit cellular mitosis and/or DNA
synthesis which would prevent cellular proliferation in tumor formation as seen by Zagon
and Mclaughlin (1981).
Although the mechanisms causing these results were still unclear,
Balasubramanian et al (2001) evaluated hypoxic cultures of murine heart endothelial cells
(mEC), human umbilical vein endothelial cells (HUVECs), and rat cardiomyocytes to
analyze how exogenous morphine might interfere with VEGF angiogenic signaling.
Normally, endogenous VEGF binds to VEGFR-1/2 (flt-1/flk-1) tyrosine kinase receptors
to induce gene expression and ultimately endothelial proliferation resulting in the
angiogenic growth of the microvasculature in conditions such as myocardial infarctions
and tissue ischemia. After the cells were cultured in hypoxic conditions and treated with
either morphine or saline for 24 hours, results demonstrated that VEGF was significantly
increased in cells that were treated with saline and exposed to hypoxic conditions, but
morphine-treated hypoxic cells showed a dose dependent decrease in VEGF expression.
Interestingly, in all cell types, when the µ-receptor antagonist naloxone was applied
simultaneously with morphine, the morphine-induced inhibition of VEGF expression was
reversed and expression closely resembled the saline-treated hypoxic cell cultures. Their
study suggested that morphine interferes with VEGF expression in both hypoxic cardiac
myocytes and hypoxic HUVECs, reducing the likelihood of endothelial cell survival in
ischemic tissues due to decreases in angiogenesis.
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Roy et al (2003) analyzed the effect of morphine on serum VEGF increases
during myocardial infarctions due to decreased oxygen tension and upregulation of the
transcription factor hypoxia inducible factor-1 alpha (HIF-1a) in hypoxic tissues. It was
hypothesized that morphine administration may inhibit myocyte VEGF expression by
inhibiting HIF-1a and/or ERK 1/2 MAP kinase signal transduction pathways leading to
decreased endothelial cell proliferation and vessel sprouting. To test this hypothesis, in
vitro rat cardiac tissue and cultures of cardiac myocytes were placed in a hypoxic
chamber and infused with one dose of either 100 ng/ml morphine or saline. Results
demonstrated morphine-induced inhibition of specific VEGF isotypes and HIF-1a
expression and a significant decrease in the binding of HIF-1a to the VEGF activation
promoter. In addition, in vivo analysis of hypoxic rat cardiac tissue showed significantly
decreased VEGF expression in the tissues surrounding the induced infarct, inhibited HIF1a expression in the same region and a decreased amount of phosphorylated (active) ERK
1/2 when compared to total ERK concentrations. This analysis by Roy et al (2003)
reiterates the study by Balasubramanian et al (2001) as both demonstrate morphine’s
ability to inhibit cardiac myocyte VEGF synthesis and interrupt specific angiogenic
signal transduction pathways in hypoxic tissues. When considering buprenorphine, a
commonly used morphine derivative, as a post-operative analgesic therapy, possible
alterations in mitogen production and subsequent decreases in endothelial cell
proliferation need to be evaluated to ensure that proper tissue perfusion is attained.
In addition to studies strictly evaluating morphine’s effects on angiogenesis, Lam
et al (2008) hypothesized that prolonged use of morphine not only impairs angiogenesis
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but can prevent the mobilization of endothelial progenitor cells in adult vasculogenesis
resulting in decreased wound healing. Using a mouse dermal wound model, mice were
subjected to excisional wounds and placed in either the intraperitoneal (IP) administered
high-dose 20 mg/kg·day morphine or saline treatment groups. Results after 14 days
showed an increased number of circulating BM-EPCs in both treatment groups indicating
that excisional wounds stimulated their release, but a significant decrease in the amount
of circulating BM-EPCs in the morphine treated group was seen compared to control. As
a result, delayed wound healing in vivo and quantities of negatively charged toxic
superoxide anion (O2-) in the wound tract were significantly increased in the morphine
treated mice. This experiment yields evidence that high systemic doses of morphine
negatively influence angiogenesis and endothelial progenitor cell distribution, leading to
delayed wound healing and an increase in oxidative stress.
With a large amount of research demonstrating the tendency for morphine to
inhibit angiogenesis, vasculogenesis and subsequent new vessel formation, a study by
Gupta et al (2002) showed that morphine actually stimulates angiogenesis by activating
the MAP kinase ERK1/2 pathway for gene expression; a pathway normally stimulated by
VEGF binding VEGFR-1 receptors on endothelial cells. In neuronal cells, this MAP
kinase ERK1/2 pathway is stimulated by morphine binding the specific µ3-opioid
receptor, suggesting a similar increase in cellular proliferation could be induced if
morphine bound a similar µ3-opioid receptor found on vascular endothelial cells (Stefano,
1995). Gupta et al used morphine-treated, saline-treated (control), and VEGF-treated
groups of cultured human dermal microvascular endothelial cells (HDMECs), murine
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Matrigel angiogenesis assays, and murine breast tumor xenografts to analyze differences
in angiogenesis. Results showed morphine increased HDMEC proliferation in culture
comparable to cultured cells incubated in vascular endothelial growth factor (VEGF)
alone. In this mouse Matrigel study, morphine-only treated mice had increased
endothelial tube formation and neovascular growth similar to VEGF-only treated mice,
but at high concentrations the morphine treated Matrigel cultures showed significant
endothelial cell cytotoxicity creating aggregates of dead cells with no endothelial tube
formation or neovascularization. In addition, results demonstrated morphine induced
stimulation of the MAPK/ERK signaling pathway in HDMECs, prevented apoptosis by
stimulating cell survival signal Akt and increased breast tumor xenograft volume by
amplifying tumor neovascularization. After analyzing these results, Gupta et al
concluded that morphine stimulated the MAPK/ERK 1/2 signal transduction pathway in
vascular endothelial cells normally targeted by endogenous VEGF, leading to enhanced
cellular proliferation and increased angiogenic activity. These findings conflict with
results acquired by Roy et al (2003) and Balasubramanian et al (2001), which suggested
morphine caused decreased angiogenesis by inhibition of signal transduction pathways
including MAPK/ERK 1/2, leading to reduced VEGF production and endothelial cell
proliferation in cultures of rat cardiac myocytes, murine heart endothelial cells (mEC),
and HUVECs. Although all three studies demonstrated these changes in vascularization
by Western Blot analysis for MAPK/ERK 1/2 and Akt proteins and reporter assays for
CD31 or VEGF, the inhibitory effects of morphine on VEGF production and
angiogenesis could only be reversed with the addition of µ-receptor antagonist naloxone
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in studies by Balasubramanian et al (2001) and Roy et al (2003). In the study by Gupta et
al (2002), the addition of naloxone did not inhibit MAPK/ERK 1/2 production and
endothelial cell proliferation as would be expected if angiogenesis was stimulated by
morphine alone suggesting that separate angiogenic signaling pathways could have been
a contributing factor to the reported increases in neovascularization.
A subsequent study by Poonawala et al (2004) theorized that morphine stimulates
the production of nitric oxide synthase (NOS) which creates the potent vasodilator nitric
oxide (NO) and results in the repair of wounded tissue via tissue granulation, cellular
proliferation and angiogenesis. Poonawala et al used a topical application of morphine
on a rat open-wound healing model to evaluate possible NO-signaling via cytokine-like
stimulation. Morphine and two other opioid derivatives, hydromorphone and fentanyl,
were applied to ischemic excisional wounds twice daily. Wounds were grossly observed
and at the end of eight days wound scars were collected and evaluated for microvessel
density, collagen formation, and nitric oxide synthase (NOS) concentrations. Results
indicated that fentanyl out of the three opioid creams had the highest increase in wound
healing (66%) with hydromorphone second (55%) and morphine third (42%) compared
to control (15%). For all treatment groups, wound healing was dose dependent with
higher concentrations resulting in significant increases in granulation tissue formation
and accelerated wound closure. Histologically, fentanyl treated wounds most closely
resembled normal tissue and had significant increases in angiogenesis, cell proliferation
and collagen content compared to controls. Immunofluorescent staining also
demonstrated an upregulation of VEGF receptor Flk-1 on the surface of endothelial cells
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indicating a possible increase in cell proliferation due to augmented VEGF angiogenic
signaling. In addition, all three opioids resulted in increased concentrations of NOS in
the dissected scar tissue suggesting nitric oxide formation significantly contributed to the
accelerated wound healing. Contrary to previous work indicating an inhibition of vessel
formation by morphine, this study demonstrates that topically applied opioids can
expedite wound healing by increasing endothelial cell proliferation, intracellular
signaling and angiogenesis via increased VEGF receptors or nitric oxide signaling in a
cytokine-like manner similar to VEGF.
With conflicting data regarding the effect of opioids on angiogenesis,
vasculogenesis, and wound healing, alternative post-operative analgesics have to be
considered to provide patient comfort and maintain tissue viability, especially in
conditions resulting in cellular hypoxia and ischemia, such as organ transplantation.
Common alternatives to buprenorphine, morphine, and other opioid derivatives are a
group of medications referred to as non-steroidal anti-inflammatory drugs (NSAIDs).
These include ibuprofen, naproxen and meloxicam.

Meloxicam
Meloxicam is an NSAID that exhibits potent analgesic and anti-inflammatory
properties with minimal deleterious gastrointestinal and renal effects. Chosen from an
arranged drug design search of different tautomerizations and structural substitutions of
the original oxicam chemical structure, meloxicam was created by adding a 5-methyl-2thiazolyl at N-1 and a hydroxyl to the 1,2-benzothiazine at C-4 (Amzoiu, 2010;
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Engelhardt, 1995). The addition of the methyl in the thiazolyl group created a third
generation bioisosteric oxicam compound resulting in effective analgesia with quickly
eliminated metabolites (Schmid, 1995a). Studies have demonstrated efficient, safe pain
amelioration with meloxicam administration (Engelhardt, 1995).
Well absorbed through oral, subcutaneous, and intravenous routes, meloxicam has
an 89-99% bioavailability and binds strongly to plasma albumin, reaching a mean
maximum plasma concentration within 2-5 hours (Schmid, 1995a). Transported through
the vasculature to sites of agonist receptor activation or cell damage, meloxicam binds
preferentially to cyclooxygenase-2 (COX-2), a catalytic enzyme that ultimately oxidizes
the cleaved membrane phospholipid (20:4ω6) arachidonic acid (AA) into the prostanoid
precursor prostaglandin H2 (PGH2) (Engelhardt, 1996; Vane, 1971). The resulting PGH2
is the substrate for several prostaglandin synthases creating various isoforms of the
prostanoid bioactive mediators thromboxane, prostacyclin, and prostaglandin to quickly
propagate inflammatory responses in an autocrine and paracrine dependent manner
(Boron & Boulpaep, 2008). When meloxicam binds to COX-2, it inhibits the enzyme’s
catalytic ability preventing the conversion of AA into PGH2 and the formation of
inflammation-mediating prostanoids (Engelhardt, 1996; Vane, 1971). With decreased
inflammation signaling molecules, the pain and symptoms associated with acute and
chronic inflammation are alleviated.
The preferential binding selectivity of meloxicam to COX-2 over homologous
enzyme cyclooxygenase-1 (COX-1) is what differentiates meloxicam from many of its
oxicam-derived NSAID precursors. Prescribed to treat osteoarthritis, rheumatoid arthritis,
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and often recommended for post-operative inflammation and analgesia, meloxicam
steady-state plasma concentrations and extended pain relief can be reached within 5-6
hours and maintained with once-daily dosing (Busch, 1998a; Busch, 1989b). With an
average elimination half-life of 15-20 hours, meloxicam undergoes extensive hepatic
biotransformation into several inactive metabolites before being excreted (Schmid,
1995a). In the liver, the Cytochrome P450-2C9 enzyme metabolizes 60% of absorbed
meloxicam by oxidation reaction into the primary metabolite 5’-carboxy meloxicam,
while both Cytochrome P450-2C9 and Cytochrome P450-3A4 transform the remaining
40% into three additional inactive metabolites (Chesne, 1998). All four
pharmacologically inert compounds are subsequently excreted in urine and feces (Schmid,
1995a; Schmid, 1995b).
In both murine and human reproductive systems, COX-2 enzymatic activity has
been identified in ovarian blood vessels, follicular theca blood vessels, interstitial cells of
the ovarian stroma, and the endometrium (Quintana, 2008). In humans, immunostaining
of ovarian tissue samples identified intense staining of COX-2 enzymatic activity colocalized with VEGF expression on the outer surface epithelium of ovarian blood vessels,
and several studies have observed increases in both COX-2 activity and VEGF in luteal
phase ovary during the menstrual cycle (Ferrara, 1998; Li, 1994; Stavreus-Evers, 2005).
In a study by Xin et al (2007), one of the products of COX-2 prostanoid
production, prostaglandin E2 (PGE2), has been shown to stimulate angiogenesis in the
endometrium and ovarian follicles by stimulating VEGF production. Prostaglandin E2
(PGE2) has also been shown to simultaneously inhibit vascular endothelial cell apoptosis
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via activation of the Bcl-2 oncogene. Using ovarian tumor inoculated nude mice,
meloxicam was administered to inhibit endogenous VEGF and COX-2 activity and
subsequent PGE2 production to evaluate their angiogenic effects in vivo. Results
demonstrated the inhibition of both PGE2 and VEGF via inactivation of COX-2
significantly reduced tumor size, decreased microvessel density, and increased apoptosis
within the ovarian cancer growth site. It was hypothesized by these researchers that the
reduced formation of PGE2 due to the inhibition of COX-2 activity by meloxicam led to a
decrease in anti-apoptotic proteins such as Bcl-2. These findings corroborated earlier
studies by Kendall et al (1996) that demonstrated an overexpression of COX-2 enzyme
resulted in increased production of pro-angiogenic factors including VEGF. In addition,
Howe et al (2005) performed studies with COX-2 null (-/-) mice that demonstrated
decreases in VEGF, ligand ang-1 and ang-2, and VEGF receptor Flk-1. In COX-2 (-/-)
mice, these decreases in multiple pro-angiogenic mitogens produced significantly
decreased microvessel size and density in genetically induced mammary tumors
compared to wildtype (wt) mouse tumors. This study reinforces results by Xin et al
(2007) that showed exogenous inhibition of COX-2 by manually administered specific
COX-2 inhibitors also reduces microvessel density and VEGF production in vivo.
To evaluate a possible pathway for the NSAID induced decrease in angiogenesis,
a study by Jones et al (1999) inoculated human microvascular endothelial cells
(HMVECs) and rat aortic endothelial cell Matrigel mesh with non-selective COX-1/2 and
selective COX-2 inhibitors. The resulting reduction of formed vascular structures in the
Matrigel mesh after administration of both the selective and the non-selective COX
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inhibitor indicated a significant decrease in angiogenesis. In addition, both types of
NSAIDs inhibited bFGF and VEGF induced MAP kinase ERK 1/2 activity and ERK2
translocation into the nucleus, both activities being necessary for in vivo and in vitro
angiogenesis. Interestingly, exogenously added PGE2 and prostacyclin only resulted in a
partial reversal of the angiogenic inhibition caused by co-culturing the cells with NSAIDs.
This study provided evidence that prostaglandins generated in endothelial cells by COX2 are involved in the regulation of angiogenesis but act in conjunction with other factors.
These findings resemble those found by Schmassmann et al (1998) which demonstrated a
decreased PGE2 production in areas of gastric ulcerations in rats that were given a
selective COX-2 inhibitor, resulting in decreased angiogenesis and delayed gastric wound
healing.
It is important to take into consideration the possibility of anti-angiogenic side
effects when considering selective COX-2 inhibitors such as meloxicam for use as postoperative analgesia since recent studies have demonstrated their direct interference with
neovascularization by preventing mitogenic signaling. In a study by Leahy et al (2002)
time-release pellets containing pro-angiogenic signal bFGF were implanted into the
corneal pocket of rats, leading to an augmentation of local angiogenesis. When a COX-2
specific inhibitor was implanted simultaneously, results indicated a decrease in
angiogenesis, decreased localized PGE2, enhanced cellular apoptosis, and decreased
endothelial cell proliferation, suggesting that COX-2 stimulated prostaglandin production
is necessary even in the presence of elevated vascular mitogen bFGF. In a related study,
Leahy et al (2002) applied the same selective COX-2 inhibitor to nude mice that had
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received colon cancer cell xenografts and found increased tumor cell apoptosis and
decreased endothelial cell proliferation, indicating an inhibition of angiogenesis leading
to decreased vascular perfusion of the xenograft tissue.
In a study by Efstathiou et al (2005) using murine endometrium allografts, the
effects of selective COX-2 inhibitors on surgically induced endometriosis were evaluated.
After autotransplanting 2 mm sections of endometrium into the abdominal cavities of
mice, post-operative injections of either saline (control) or the NSAID celecoxib, a COX2 specific inhibitor, were given. Results demonstrated well-established large, fluid-filled
cystic lesions where transplanted tissue was applied indicating endometriosis was
successfully induced in animals receiving saline, and reduced or eliminated lesions and
cysts where the transplanted tissue was applied in the mice receiving celecoxib indicating
a significant decrease in the establishment of the endometrial allografts and subsequent
endometriosis. When the NSAID treatment was removed, residual endometrial cells near
the transplant area proceeded to cause lesions and cysts typical of endometriosis although
the vessel density of the endometrial tissue below the endometrial allografts was not
significantly different between the control group and celecoxib group of animals. In
addition, when NSAID treatment was initiated in a separate group of animals with
already established endometriosis lesions via endometrial allograft, no significant
reduction of cysts or lesions at the transplant site was observed. This study suggests that
angiogenic inhibition produced by the COX-2 specific NSAID celecoxib does not affect
already established vascular pathways but inhibits endometrial blood vessel angiogenesis
by decreasing COX-2 mediated prostaglandin production.
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The decrease in angiogenesis via selective COX-2 inhibitors such as meloxicam
can be a remarkably potent supplement for the treatment of solid tumors and conditions
such as endometriosis, but it can be debilitating for conditions that require sufficient
vascularization necessary for tissue viability such as ulcer healing and transplantation.
Although meloxicam offers comprehensive pain relief that ameliorates the discomfort of
post-operative pain and inflammation, the repercussions of decreasing inflammatory
prostaglandin production such as PGE2 could jeopardize the formation of sufficient
microvasculature leading to inadequately perfused tissues and an increase in cell death.
When considering the mode of action of selective COX-2 inhibitors such as meloxicam,
the general research consensus indicates that meloxicam inhibits angiogenesis via the
decreased production of important inflammatory prostaglandins. This suggests that
meloxicam and other COX-2 specific NSAIDs could decrease vessel formation in murine
ovary allografts if given as a post-operative analgesic resulting in poor perfusion and cell
death in the transplanted tissue. Alternatively, conflicting results suggest that using
buprenorphine or other µ-opioid agonists could either prevent or enhance sufficient
neovascularization when given as a post-operative analgesic because morphine
derivatives have been implicated in both the inhibition and enhancement of angiogenesis.
Comparative studies analyzing the effects of post-operative analgesics meloxicam and
buprenorphine on angiogenesis need to be considered to maximize subject comfort and
still achieve successful vascularization after surgeries such as murine ovary
allotransplantation.
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Vessel identification and quantitation
Research has shown that cellular hypoxia and inflammation will stimulate the
release of endogenous mitogens VEGF, bFGF, and angiopoietins 1 & 2 from both the
host bursa and grafted ovarian endothelial cells leading to angiogenesis (Dissen 1994;
Van Eyck, 2010). In response to this mitogenic cell signaling, pre-existing vessels will
begin extracellular matrix degradation, endothelial cell proliferation, and increased
branching as angiogenesis progresses (Connolly, 1989; Pepper, 1998). To sufficiently
quantify this progression, an endothelial cell surface antigen can be used to identify
proliferating endothelial cells and newly formed microvessel networks. The most widely
used endothelial cell epitope is the cell-cell adhesion molecule platelet endothelial cell
adhesion molecule-1 (PECAM-1) also known as cluster of differentiation 31 (CD31)
(Vermeulen, 1996). When compared to other cell surface antigens that only stain
medium to large vessels such as VEGF receptor Flk-1, von Wildebrand factor or CD34,
CD31 consistently displays a homogenously strong staining of all vessel sizes including
microvessels and vessels undergoing active angiogenesis (Pusztaszeri, 2006; Wang,
2008). In addition, CD31 is found in large quantities on endothelial cell surfaces with
concentrations at cell-cell junctions, further associating CD31 with its role in cell
adhesion and migration during angiogenesis (DeLisser, 1997; Zocchi, 1996). This cell
surface antigen is ubiquitous on proliferating endothelial cells and is far less abundant on
other types of circulating cells such as leukocytes and platelets (Albelda, 1991). At times,
tissue macrophages may be accidentally identified using the CD31 cell surface antigen,
but the evaluation of cell morphology can be used to differentiate between cell types
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(McKenney, 2001). With minimal disadvantages, CD31 remains the best surface antigen
to use for the identification of angiogenesis and anti-CD31 immunostaining has been
published as the international standard for the assessment of microvessel density
(Giatromanolaki, 1997; Vermeulen, 1996).
To visualize the CD31 endothelial cell surface antigen, anti-CD31
immunohistochemical techniques can be used to attach a colored reporter label to an
unlabeled anti-CD31 antibody bound to the CD31 epitope (Boenisch, 2001; Renshaw,
2010). A common type of clearly identifiable colored reporter label used with light
microscopy is the red/brown chromogen 3, 3’ diaminobenzidine (DAB) (Boenisch, 2001;
Renshaw, 2010). Using this indirect immunohistochemical method to identify
endothelial cells involved in angiogenesis reduces non-specific cell surface antigen
staining and results in red/brown DAB reporter labeled layers of interlaced vascular
endothelial cells outlining new capillary networks that are easily visible with a light
microscope (Vandesande, 1988).
The present study elucidates the effects of two types of analgesics on
angiogenesis in murine ovary allografts by evaluating total number of vessels, individual
vessel parameters such as branch number and length, percent vessel density, and vessel
location to determine which class of analgesics would provide adequate pain relief with
minimal inhibition of the new vessel formation necessary for successful ovarian
transplantation. As described above, the analgesics chosen for evaluation in this study
include meloxicam, a non-steroidal anti-inflammatory selective COX-2 inhibitor and the
opioid derivative buprenorphine, a potent µ-receptor agonist. It is hypothesized that the
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total number of superficial vessels, vessel elements, and percent vessel density indicative
of angiogenesis will show alterations after post-operative administration of both
meloxicam and buprenorphine compared to saline controls. When considering the
ovarian location that would most likely have the highest vascularized area, the shortrange paracrine activity of mitogens such as VEGF released from hypoxic vascular
endothelial cells at the ovary surface suggest that tissue analysis at a depth of
approximately 36 µm will encompass the highest number of vessels across treatment
groups while still remaining decreased when compared to saline controls. Although these
hypotheses are manifested from the results of several previous studies evaluating the
effects of opioid and NSAID analgesics in various animal models, cell culture types, and
using assorted administration protocols, it would be beneficial to identify a particular
analgesic as having no significant difference in angiogenesis from a saline control group
(Balasubramanian, 2001; Efstathiou, 2005; Gupta, 2002; Jones, 1999; Lam, 2008). These
findings show that a specific analgesic could be used to provide ample relief from postoperative discomfort while not impeding adequate angiogenesis to maintain tissue
viability and ensure transplantation success.
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MATERIALS AND METHODS
Animals
Seven-week old female CBA/J recipient mice were purchased from the Jackson
Laboratory (Sacramento, CA) and housed five females per 29 x 22 x 14 cm cage in
accordance with University Animal Care Guidelines with approval by the San José State
University Institutional Animal Care and Use Committee (approval number 959). Mice
were housed under controlled conditions including a 12L:12D fluorescent 60 lm/W light
cycle and ad libitum access to food (Purina Mouse Chow 5008: 23.5% protein, 6.5% fat;
Purina Mills, St. Louis, MO) and water (deionized) until animals were approximately 11
months of age (Cargill, 2003; Mason, 2009). Two weeks before surgery dates, donor sixweek old CBA/J mice were purchased from Jackson Laboratory and housed in the same
conditions. To ensure proper estrus cycling, age matched male CBA/J mice were housed
in adjacent cages and under similar conditions with two males per cage (Whitten, 1956).

Ovarian transplantation and treatment administration
Using the surgical procedures previously reported by Cargill et al (2003), the 11month old recipient mice were anesthetized with an intraperitoneal (IP) 0.65 mg/kg body
weight dose of sodium pentobarbital (Lundbeck Inc., Deerfield, IL). The anesthetized
recipient mice were shaved and antiseptically cleaned bilaterally at the dorsolateral
abdomen and maintained on a heating pad (Conair, Shelton, CT) while ovariectomized
(the bilateral surgical removal of ovaries). Ovaries from eight-week old CBA/J donor
mice were surgically placed into the empty ovarian bursa of the aged recipient female and
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the bursa was closed with 7-0 Ethilon nylon filament (Ethicon, San Angelo, TX). The
abdominal wall was closed using 5-0 Ethicon chromic gut suture (Ethicon, San Angelo,
TX) and wound clips (Becton Dickinson and Company, Sparks, MD) were applied to
close the skin. Wound clips were removed seven days post-operatively. Animals were
recovered individually in a monitored, heated environment until fully conscious and
remained in individual 17 x 29 x 13.5 cm cages until the conclusion of the experiment
(Cargill, 2003; Mason, 2009). One recipient mouse died during surgery most likely due
to a complication from the sodium pentobarbital anesthetic. This mouse, in addition to a
second mouse that died prematurely due to a seizure condition associated with the CBA/J
mouse strain, were excluded from the study reducing the saline treatment group n to
seven (Fuller, 1967).
Pre-operatively, recipient mice were randomly assigned to one of three treatment
groups: meloxicam, buprenorphine, or 0.9% saline control. In the meloxicam treatment
group, nine mice received intraperitoneal 5 mg/kg doses of meloxicam (Boehringer
Ingelheim, St. Joseph, MO). In the buprenorphine group, nine recipient mice received an
intraperitoneal 0.05 mg/kg buprenorphine (Reckitt Benckiser, Hull, England) dose, and
the remaining eight mice received intraperitoneal 0.9% saline (Vedco, Inc., St. Joseph,
MO) doses in volumes similar to the buprenorphine and meloxicam. Analgesia doses
were chosen according to current veterinary recommendations. Doses of meloxicam,
buprenorphine, and saline were given every 12 hours for 48 hours post-operatively with
the first dose given after ovary allotransplantation and before anesthetic recovery.
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Fixation and preservation of ovaries
For non-biased double-blind analysis, all female recipient mice were randomly
assigned new identification numbers and sacrificed by cervical dislocation between 73-78
days post-transplantation. One ovary from each mouse was placed into individual
labeled 5 ml sterile glass vials (Wheaton Science Products, Millville, NJ) containing 4 ml
of IHC Zinc fixative (BD Biosciences, San Diego, CA). The vials were sealed with
parafilm (Parafilm, Neenah, WI) to prevent leakage and kept at 4° C for 24 hours. When
incubation was complete new labeled 5 ml sterile glass vials were filled with 4 ml of
sterile RNAse-free phosphate buffered saline (PBS) (Boston Bioproducts, Ashland, MA).
Fine tissue forceps were used to transfer the ovary from the Zinc fixative to the
corresponding vial of PBS, making sure to clean the forceps between each transfer. New
vial lids were secured with parafilm and placed in labeled cardboard shipping containers
at 4° C. The labeled ovary vial containers were then packed in ice packs lined styrofoam
coolers and shipped overnight to IHC World LLC (Ellicott City, MD) for CD31
immunohistochemistry antibody binding and 3.3’-Diaminobenzidine (DAB) chromogen
staining.

CD31 Immunohistochemistry procedure
Upon receipt of samples the 5 ml labeled vials were removed from 4° C and
ovaries were transferred to room temperature RNAse-free phosphate buffered saline
(PBS) in labeled 1.5 ml microcentrifuge tubes (Fisher Scientific, Fair Lawn, NJ). The
ovaries were washed in PBS-Tween20 (Fisher Scientific, Fair Lawn, NJ) for 30 minutes
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followed by incubation in rabbit anti-mouse CD31 primary antibody (Thermo Scientific
Pierce, Rockford, IL) diluted 1:100 using IHC-Tek Antibody Diluent (IHC World,
Ellicott City, MD) on a shaker at room temperature for 16 hours. Following the
incubation, the ovaries were washed in PBS-Tween20 three times for 30 minutes each
and incubated on a shaker in 3% Peroxidase Blocking Solution (Vector Laboratories,
Burlingame, CA) for 20 minutes at room temperature. After an additional three washes
in PBS-Tween20 for 30 minutes each, the ovaries were incubated in biotinylated goat
anti-rabbit secondary antibody (Thermo Scientific Pierce, Rockford, IL) diluted 1:500
using IHC-Tek Antibody Diluent on a shaker at room temperature for 16 hours.
Following this incubation, the ovaries were washed in PBS-Tween 20 three times for one
hour each and incubated on a shaker in a 1:500 dilution of HRP-Streptavidin (Biolegend,
San Diego, CA) for 16 hours at room temperature. The ovaries were then washed in
PBS-Tween 20 three times for one hour each and incubated in a 1:4 dilution of 3.3’Diaminobenzidine (DAB) Chromogen (Fisher Scientific, Fair Lawn, NJ) for 10-15
minutes at room temperature, removing the ovaries when a uniform dark brown color had
been achieved. The ovaries were then rinsed with three washes of PBS-Tween 20 at 10
minutes each and placed in new labeled 1.5 ml microcentrifuge tubes containing 1 ml of
room temperature 50% glycerol (Hampton Research, Aliso Viejo, CA) in PBS. The
ovaries were incubated in the 50% glycerol/PBS solution for 10-20 minutes until the
ovary sank to the bottom of the tube. The ovaries were removed and placed in a 70%
glycerol in PBS solution and the labeled tubes were stored at 4° C. The ovaries were
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shipped from IHC World LLC (Ellicott City, MD) overnight to San Jose State University
at 4° C.

Ovarian tissue embedding and slide processing
For the dehydration procedure before paraffin embedding, the ovaries were
removed from the 4° C 70% glycerol suspension and washed three times with room
temperature PBS for 10 minutes each. After washing, ovaries were incubated in labeled
1.5 ml microcentrifuge tubes containing room temperature 70% ethanol (Histo-chem,
Jefferson, AR) twice for one hour each. Ovaries were incubated in 80% ethanol for one
hour, 95% ethanol (Histo-chem, Jefferson, AR) for one hour and three incubations of
100% ethanol (Histo-chem, Jefferson, AR) at room temperature for 1.5 hours each.
Ovaries were placed into labeled 1.5 ml microtubes containing 100% xylene (SigmaAldrich, St. Louis, MO) at room temperature and incubated for three washes at 1.5 hours
each. The ovaries were placed into individual labeled 200 ml beakers containing 60° C
Paraplast Plus (Covidien, Mansfield, MA) paraffin wax and incubated for two hours. The
paraffin embedded ovaries were then placed into labeled embedding cassettes (Fisher
Scientific, Fair Lawn, NJ), covered in Paraplast plus paraffin wax and allowed to dry for
six hours. After a minimum of six hours of drying time, the paraffin embedded ovaries
were placed into the Leica Histoslide 2000 sliding microtome (Leica Microsystems,
Buffalo Grove, IL). To collect the surface layers for vascularization analysis, 18 µm
ovary sections were taken from the “top” of the wax embedded ovary and mounted onto
labeled TruBond 380 microscope slides (TruBond, Woodstock, MD) with a fine tip
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paintbrush. Sectioning continued until the brown DAB staining was limited to the
periphery of the remaining ovarian tissue indicating that the surface layers had been
removed and the middle of the ovary had been reached. The mid-sections of ovary were
sectioned at 40 µm and placed on separate labeled Trubond microscope slides for use in
another project. The remaining 160-180 µm of embedded ovarian tissue was sliced into
18 µm sections until all ovary tissue had been sectioned. All 25 ovaries were sectioned,
mounted onto labeled TruBond 380 microscope slides, air dried for 30 minutes then
baked in a Precision Scientific 25EM oven (Thermo Electron Corporation, Marietta,
Ohio) at 45° C for 16 hours.
To rehydrate ovary sections, the slides were immersed twice in 100% xylene for
10 minutes each and then twice in 100% ethanol for 10 minutes each. Slides were then
immersed into 95% ethanol for five minutes, 70% ethanol for five minutes and 50%
ethanol for five minutes. The slides were rinsed with deionized water and placed in PBS
for 10 minutes. After rehydration, excess PBS was wicked from the surface and back of
slide using Kimwipes (Kimberly-Clark, Irving, TX). A 0.5” line of DPX Histology
Mountant (Sigma-Aldrich, St. Louis, MO) was placed along the center of each 50 x 24
mm rectangular glass coverslip (Fisher Scientific, Fair Lawn, NJ) and the Trubond slide
was inverted and placed tissue section side down onto the mountant and a light pressure
was applied to remove trapped air bubbles. Excess mountant was removed from the sides
and bottom of the slide. The slide with attached coverslip was placed upright and
allowed to dry in a covered tray for 24 hours.
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Image capturing and processing
Pictures were taken of each tissue section using a Leica EC3 camera (Leica
Microsystems, Buffalo Grove, IL) mounted on a Leica DMIL LED inverted microscope
(Leica Microsystems, Buffalo Grove, IL). Each 18 µm section was photographed at 50100x to capture the whole tissue cross-section and at 400x for identification of individual
vessels, with each picture identified by group number, slide number, section number, and
picture number.
After all tissue sections were photographed, only images from the third
(approximately 54 µm from the ovary surface), fifth (approximately 90 µm from the
ovary surface), and seventh (approximately 126 µm from the ovary surface) sections
from the “top” of each ovary and third, fifth, and seventh sections from the opposite
“bottom” of the ovary were used for subsequent image analysis. For these images,
Graphic Converter software version 8.8.2 (Lemke Software, Peine, Germany) was used
to crop each individual photo to prevent image overlap and remove shadow resulting in a
section of tissue with dark vascular structures present (Figure 1A). Each picture was then
opened in Image J software 1.47v 32-bit (National Institute of Health, Bethesda, MD) and
the “split channels” command was run. This split the red, green and blue channels of the
source image into three separate grayscale images with a white background, leaving the
cell data in shades of dark grey. Using the green image, the “invert” command was run,
which created a new image consisting of a black background and transformed the cell
data to shades of light grey (Figure 1B). The image was saved and the auto threshold was
set to “default dark.” The upper and lower threshold ratio was then set to 123/255 which

	
  
34	
  

	
  

best replicated the vascular structures from the original cropped images. The image was
converted to binary by setting the black background option to “false” and running the
“make binary” command with the “thresholded remaining black” command, creating a
binary image of blacks and whites (Figure 1C). This binary image represented the
overall number of vessels present and was used to evaluate vessel density by calculating
the percentage of black pixels per image before the image was converted into the
skeletonized representation. The image was saved and the “skeletonize” command then
the “invert” command were run, which provided a black background with a white
vascular skeleton image (Figure 1D).
Using Analyze Skeleton version 2.0.0 for Image J (Ignacio Arganda-Carreras,
Madrid, Spain) the “analyze skeleton” command [2D/3D] was run with the “prune”
setting at “none.” The results were saved in an Excel version 14.3.9 (Microsoft,
Redmond, WA) spreadsheet and “total number of vessels,” “total number of branches,”
“total number of junctions,” “average number of branches per vessel,” “average number
of junctions per vessel,” “mean branch length (µm),” “mean vessel length (µm),” and
“percent vessel density” data for each individual image was input into separate Excel
spreadsheets organized by ovary group number, section number, and image number
(Doukas, 2006).
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Statistical Analysis
After each image had been analyzed, each individual image Excel spreadsheet
was condensed into 25 spreadsheets organized by group number only. Numerical data
from whole ovary analysis categories “total number of vessels,” “total number of
branches,” “total number of junctions,” and “percent vessel density” were condensed
onto a single sheet and organized by group number. On a separate sheet, individual
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vessel numerical data from categories “average number of branches per vessel,” “average
number of junctions per vessel,” “mean branch length (µm),” and “mean vessel length
(µm)” were condensed and organized by group number. For both ovary and individual
vessel data spreadsheets, mean values were calculated by averaging all the values from
each individual image in each group number in each category and all averages were
placed into a separate Excel spreadsheet. After all categories had been averaged and the
data separated by group number, each group number was condensed further by treatment.
One-way Analysis of Variance (ANOVA) and post-hoc Tukey’s Honest Significant
Difference (HSD) statistical tests were used to compare the calculated means of each
category between the saline treatment group (n= 7), the buprenorphine treatment group
(n= 9), and the meloxicam treatment group (n= 9), and between the buprenorphine and
meloxicam treatment groups. All One-Way ANOVAs and Tukey’s HSD pairwise
comparisons were performed using SPSS Statistics software (IBM, Armonk, NY).
Before each group was identified by treatment, each group number was also
separated by ovary section number (third, fifth, or seventh) and the whole ovary analysis
mean for “total number of vessels,” “total number of branches,” “total number of
junctions,” “average number of branches per vessel,” “average number of junctions per
vessel,” “mean branch length (µm),” “mean vessel length (µm),” and “percent vessel
density” were calculated from each image value in each ovary section to compare means
between the third, fifth, and seventh sections. For each ovary, polar opposite third
section “total number of vessels,” “total number of branches,” “total number of junctions,”
“mean branch length (µm),” “mean vessel length (µm),” “average number of branches
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per vessel,” “average number of junctions per vessel,” and “percent vessel density”
means were averaged and One-Way ANOVA with post-hoc Tukey’s HSD statistical tests
were used to compare means between treatment groups. In two separate analyses, polar
opposite fifth section and polar opposite seventh section “total number of vessels,” “total
number of branches,” “total number of junctions,” “average number of branches per
vessel,” “average number of junctions per vessel,” and “percent vessel density” means
were compared between treatment groups using One-way ANOVAs and post-hoc
Tukey’s HSD statistical tests. Since fifth and seventh section means for “mean branch
length (µm)” and “mean vessel length (µm)” did not show homogeneity of variance,
results were analyzed using Kruskal-Wallis Analysis of Variance (Kruskal-Wallis
ANOVA) non-parametric tests. Kruskal-Wallis non-parametric comparisons were
performed using SPSS Statistics software.
For cross-sectional ovary area analysis, the area of both “top” and “bottom” third,
fifth, and seventh ovary sections were calculated in millimeters squared (mm2). For each
ovary, polar opposite third section areas were averaged and compared between treatment
groups using One-way ANOVAs and post-hoc Tukey’s HSD statistical tests. One-way
ANOVAs and post-hoc Tukey’s HSD tests were used to compare the mean area of each
polar ovary fifth section between treatment groups and the mean area of each polar ovary
seventh section between treatment groups.
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RESULTS
Superficial Vessel Analysis
Averaged “total number of vessels” in the third sections (approximately 54 µm
from the ovary surface), fifth sections (approximately 90 µm from the ovary surface), and
seventh sections (approximately 126 µm from the ovary surface) between the saline
control group (M= 31029.9 vessels, n= 7, SD= 10495.4), the meloxicam treatment group
(M= 43336.9 vessels, n= 9, SD= 9390.3), and the buprenorphine treatment group (M=
25512.1 vessels, n= 9, SD= 6433.2) were compared using One-Way ANOVA. Results
show a significant difference between the saline treatment group and the meloxicam
treatment group and between the meloxicam and buprenorphine treatment groups (F (2,
22)= 9.642, p= 0.001, Figure 2). Tukey’s HSD post-hoc pairwise comparisons also
demonstrated a significant difference between the buprenorphine treatment group and the
meloxicam treatment group (p= 0.001) and a significant difference between the saline
treatment group and the meloxicam treatment group (p= 0.028). Post-hoc comparisons
determined no significant difference between the saline and buprenorphine treatment
groups (p= 0.494). Means and standard deviations (SD) for the total number of vessels
per ovary for each treatment group are represented in Table 1.
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Figure 2. Mean number of vessels per ovary in each treatment group determined by
averaging the means from all six sections within each treatment group (n= 25). Saline
(M= 31029.9 vessels, n= 7, SD= 10495.4), meloxicam (M= 43336.9 vessels, n= 9, SD=
9390.3), buprenorphine (M= 25512.1 vessels, n= 9, SD= 6433.2). Single asterisks [*]
represent significance between saline and meloxicam (One-Way ANOVA F(2,22)= 9.642,
p= 0.028). Double asterisks [**] represent significance between meloxicam and
buprenorphine (One-Way ANOVA p= 0.001). Error bars represent 95% confidence
intervals.

Table 1. Mean and Standard Deviations (SD) for total number of vessels per ovary, total
number of vessel branches per ovary, total number of vessel junctions per ovary, and
percent vessel density [skeletonized area (µm) /section area (µm) x 100] for each
treatment. Each mean represents an average of the ovary (n= 25) section means per
treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9). Single asterisks [*]
represent significance p= 0.02-0.05. Double asterisks [**] represent significance p< 0.02.
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Analgesic
Treatment

Total Number of
Vessels per ovary
Mean

SD

Total Number of
Vessel Branches per
ovary
Mean
SD

Total Number of
Vessel Junctions per
ovary
Mean
SD

Percent
Vessel
Density
Mean SD

Saline

31029.9*

10495.4

158272.8

64472.9

69504.9

29540.2

19.7

7.2

Meloxicam

43336.9*;**

9390.3

194854.8*

36750.4

82408.4*

15892.5

17.1

4.9

Buprenorphine

25512.1**

6433.2

128819.7*

42821.2

56447.7*

20448.8

18.8

4.7

The total number of vessel branches per ovary means between the saline treatment
group (M= 158272.8 branches, n= 7, SD= 64472.9), the meloxicam treatment group (M=
194854.8 branches, n= 9, SD= 36750.4), and the buprenorphine treatment group (M=
128819.7 branches, n= 9, SD= 42821.2) were compared using One-Way ANOVA,
means and standard deviation represented in Table 1. Results show a significant
difference between the three treatment groups (F(2,22)= 4.296, p= 0.027, Figure 3) with
Tukey’s HSD post-hoc comparisons demonstrating the significance was specifically
between the buprenorphine treatment group and the meloxicam treatment group (p=
0.021). No significant difference was observed between the saline treatment group and
the buprenorphine treatment group (p= 0.454) and saline and meloxicam treatment
groups (p= 0.303).
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Figure 3. Mean number of vessel branches per treatment group determined by averaging
the means from each ovary within each treatment group (n= 25). Saline (M= 158272.8
branches, n= 7, SD= 64472.9), meloxicam (M= 194854.8 branches, n= 9, SD= 36750.4),
buprenorphine (M= 128819.7 branches, n= 9, SD= 42821.2). Single asterisks [*]
represent significance between meloxicam and buprenorphine (One-Way ANOVA
F(2,22)= 4.296, p= 0.021). Error bars represent 95% confidence intervals.

To compare the total number of junctions where the main vessel structure and
extending branches connect, the total number of junctions per ovary were averaged and
the saline treatment group (M= 69504.9 junctions, n= 7, SD= 29540.2), meloxicam
treatment group (M= 82408.4 junctions, n= 9, SD= 15892.5), and buprenorphine (M=
56447.7 junctions, n= 9, SD= 20448.8) were compared by One-Way ANOVA. Results
indicated no significant difference in the total number of junctions between the main
vessel structure and extending branches across the three treatment groups (F(2,22)=
3.147, p= 0.063, Figure 4). Tukey’s HSD post-hoc comparisons between the
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buprenorphine treatment group and the meloxicam treatment group showed a significant
difference (p= 0.05), but pairwise comparisons between the saline treatment group and
the buprenorphine treatment group (p= 0.477), and saline and meloxicam treatment
groups (p= 0.485) were not significantly different. The averaged means and the standard

Mean Number of Vessel Junctions (Ovary)

deviations of the total number of junctions per treatment group are represented in Table 1.
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Figure 4. Mean number of main vessel and branch junctions per treatment group
determined by averaging the means from each ovary within each treatment group (n= 25).
Saline (M= 69504.9 junctions, n= 7, SD= 29540.2), meloxicam (M= 82408.4 junctions,
n= 9, SD= 15892.5), buprenorphine (M= 56447.7 junctions, n= 9, SD= 20448.8). Single
asterisks [*] represent significance between meloxicam and buprenorphine (One-Way
ANOVA F(2,22)= 3.147, p= 0.05). Error bars represent 95% confidence intervals.

There were no significant differences in percent vessel density when measured
using the skeletonized area (µm) divided by the section area (µm) between the saline
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treatment group (M= 19.71%, n= 7, SD= 7.2), the meloxicam treatment group (M=
17.1%, n= 9, SD= 4.9), and the buprenorphine treatment group (M= 18.8%, n= 9, SD=
4.7) when compared using a One-Way ANOVA (F(2, 22)= 0.453, p= 0.642, Figure 5).
The averages of the means from each ovary separated by treatment group are represented
in Table 1.

45	
  
40	
  

Vessel Density (%)

35	
  
30	
  
25	
  
20	
  
15	
  
10	
  
5	
  
0	
  
Saline	
  

Meloxicam	
  

Buprenorphine	
  

Analgesic Treatment

Figure 5. Mean percent vessel density [skeletonized area (µm)/ section area (µm) x100]
per ovary determined by averaging the means from each ovary within each treatment
group (n= 25). Saline (M= 19.71%, n= 7, SD= 7.2), meloxicam (M= 17.1%, n= 9, SD=
4.9), buprenorphine (M= 18.8%, n= 9, SD= 4.7). Error bars represent 95% confidence
intervals.
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Individual Section Analysis
The means of the total number of vessels from the third, fifth, and seventh 18 µm
representative sections taken from each ovary pole were averaged and means per
treatment group were compared using One-Way ANOVA. The averaged means and the
standard deviations for the total number of vessels in each third, fifth, and seventh section
per treatment group are represented in Table 2. After averaging the total vessel means
from each polar third section there was no significant difference between the saline
treatment group (M= 4651.71 vessels, n= 7, SD= 2145.7), the meloxicam treatment
group (M= 5541.56 vessels, n= 9, SD= 1410.7), and the buprenorphine treatment group
(M= 4287.94 vessels, n= 9, SD= 2213) (One-Way ANOVA F(2,22)= 0.987, p= 0.389),
Figure 6).

Table 2. Mean and Standard Deviations (SD) for the averaged total number of vessels
per third (approximately 54 µm from the surface), fifth (approximately 90 µm from the
surface), and seventh (approximately 126 µm from the surface) opposite polar sections
per ovary. Each mean represents an average of the means for each appropriate section
per ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9).
Single asterisks [*] represent significance p= 0.01-0.05. Double asterisks [**] represent
significance p< 0.01.
Total Number of
Vessels per
Seventh Section
(126 µm)
Mean
SD

Total Number of
Vessels per Third
Section (54 µm)

Total Number of
Vessels per Fifth
Section (90 µm)

Mean

SD

Mean

SD

Saline

4651.71

2145.7

5540.5*

2272.5

5400.35

1626.9

Meloxicam

5541.56

1410.7

8357.39*;**

1903.5

7769.5**

2054.9

Buprenorphine

4287.94

2213

4582.83**

1042

4470.5**

1893.9

Treatment
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Figure 6. Mean total number of vessels determined by averaging the means from polar
third sections (approximately 54 µm from the ovary surface) within each treatment group
(n= 25). Saline (M= 4651.71 vessels, n= 7, SD= 2145.7), meloxicam (M= 5541.56
vessels, n= 9, SD= 1410.7), buprenorphine (M= 4287.94 vessels, n= 9, SD= 2213).
Error bars represent 95% confidence intervals.

One-Way ANOVA was used to compare the averaged total number of vessels
from each fifth ovary section from opposite poles per ovary between the saline treatment
group (M= 5540.5 vessels, n= 7, SD= 2272.5), the meloxicam treatment group (M=
8357.39 vessels, n= 9, SD= 1903.5), and the buprenorphine treatment group (M=
4582.83 vessels, n= 9, SD= 1042). Results showed there was a significant difference in
the total number of vessels across the three treatment groups (F(2, 22)= 10.969, p< 0.001,
Figure 7). Post-hoc Tukey’s HSD showed a significant difference between the saline and
meloxicam treatment groups (p= 0.012) and between the meloxicam and buprenorphine
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treatment groups (p< 0.001). No significant difference in the total number of vessels was
shown between the saline and buprenorphine treatment groups’ fifth sections (p= 0.539).

Mean Number of Vessels
(fifth section: 90 µm from polar surface)
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Figure 7. Mean total number of vessels determined by averaging the means from polar
fifth sections (approximately 90 µm from the ovary surface) within each treatment group
(n= 25). Saline (M= 5540.5 vessels, n= 7, SD= 2272.5), meloxicam (M= 8357.39
vessels, n= 9, SD= 1903.5), buprenorphine (M= 4582.83 vessels, n= 9, SD= 1042).
Single asterisks [*] represent a significant difference between saline and meloxicam
(One-Way ANOVA F(2,22)= 10.969, p= 0.012). Double asterisks [**] represent a
significant difference between meloxicam and buprenorphine (One-Way ANOVA p<
0.001). Error bars represent 95% confidence intervals.

One-Way ANOVA was used to compare the averaged total number of vessels
from each seventh section per ovary between the saline treatment group (M= 5400.35
vessels, n= 7, SD= 1626.9), the meloxicam treatment group (M= 7769.5 vessels, n= 9,
SD= 2054.9), and the buprenorphine treatment group (M= 4470.5 vessels, n= 9, SD=
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1893.9). Results showed a significant difference in the total number of vessels between
seventh sections across the three treatment groups (F(2, 22)= 7.241, p= 0.004, Figure 8).
Tukey’s HSD post-hoc pairwise comparisons demonstrated a significant difference
between the meloxicam and buprenorphine treatment groups (p= 0.003). No significant
difference in the total number of vessels was shown between the saline and
buprenorphine treatment groups (p= 0.598) and saline and meloxicam treatment groups’

Mean Number of Vessels
(seventh section: 126 µm from polar surface)

seventh sections (p= 0.052).
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Figure 8. Mean total number of vessels determined by averaging the means from polar
seventh sections (approximately 126 µm from the ovary surface) within each treatment
group (n= 25). Saline (M= 5400.35 vessels, n= 7, SD= 1626.9), meloxicam (M= 7769.5
vessels, n= 9, SD= 2054.9), buprenorphine (M= 4470.5 vessels, n= 9, SD= 1893.9).
Asterisks [*] represent a significant difference between buprenorphine and meloxicam
(One-Way ANOVA F(2,22)= 7.241, p= 0.004). Error bars represent 95% confidence
intervals.
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The mean total branch number from each polar third section was averaged and
compared across treatment groups using One-Way ANOVA. Results demonstrated no
significant difference between the saline treatment group (M= 23357.7 branches, n= 7,
SD= 11451), the meloxicam treatment group (M= 26330.1 branches, n= 9, SD= 6137.8),
and the buprenorphine treatment group (M= 24035.1 branches, n= 9, SD= 13109.1)
(F(2,22)= 0.267, p= 0.783). The averaged means and the standard deviations for the total
number of branches in each third, fifth, and seventh section per treatment group are
represented in Table 3.

Table 3. Mean and Standard Deviations (SD) for the averaged total number of branches
per third (approximately 54 µm from the surface), fifth (approximately 90 µm from the
surface), and seventh (approximately 126 µm from the surface) opposite polar sections
per ovary. Each mean represents an average of the means for each appropriate section
per ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9).
Single asterisks [*] represent significance p= 0.001. Double asterisks [**] represent
significance p< 0.001.

Treatment

Total Number of
Branches per Third
Section (54 µm)

Total Number of
Branches per Fifth
Section (90 µm)

Total Number of
Branches per
Seventh Section
(126 µm)
Mean
SD

Mean

SD

Mean

SD

Saline

23357.7

11451.0

29721.4*

2145.7

48790.0

18639.7

Meloxicam

26330.1

6137.8

69727.2*;**

15058.1

51038.6

17543.9

Buprenorphine

24035.1

13109.1

21727.9**

5122.3

44957.6

13346.5

The total branch number means from the fifth 18 µm representative sections taken
from each ovary pole were averaged and means were compared across treatment groups
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using One-Way ANOVA. Results indicated a significant difference between the saline
treatment group (M= 29721.4 branches, n= 7, SD= 2145.7), the meloxicam treatment
group (M= 69727.2 branches, n= 9, SD= 15058.1), and the buprenorphine treatment
group (M= 21727.9 branches, n= 9, SD= 5122.3) (F(2,22)= 41.462, p= 0.001, Figure 9).
Post-hoc Tukey’s HSD test showed a significant difference between the saline and
meloxicam treatment groups (p= 0.001) and between the meloxicam and buprenorphine
treatment groups (p< 0.001).

Mean Number of Vessel Branches
(fifth section: 90 µm from polar surface)
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Figure 9. Mean total number of vessel branches determined by averaging the means
from polar fifth sections (approximately 90 µm from the ovary surface) within each
treatment group (n= 25). Saline (M= 29721.4 branches, n= 7, SD= 2145.7), meloxicam
(M= 69727.2 branches, n= 9, SD= 15058.1), buprenorphine (M= 21727.9 branches, n= 9,
SD= 5122.3). Single asterisks [*] represent a significant difference between saline and
meloxicam (One-Way ANOVA F(2,22)= 41.462, p= 0.001). Double asterisks [**]
represent a significant difference between meloxicam and buprenorphine (One-Way
ANOVA p< 0.001). Error bars represent 95% confidence intervals.
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The mean total branch number from each polar seventh section was averaged and
no significant difference between the saline treatment group (M= 48790.0 branches, n= 7,
SD= 18639.7), the meloxicam treatment group (M= 51038.6 branches, n= 9, SD=
17543.9), and the buprenorphine treatment group (M= 44957.6 branches, n= 9, SD=
13346.5) (One-Way ANOVA F(2,22)= 0.200, p= 0.387) was demonstrated.
The total number of junctions where the main vessel structure and extending
branches connect from the third, fifth, and seventh polar opposite sections were averaged
and means per treatment group were compared using One-Way ANOVA. The averaged
means and the standard deviations for the total number of junctions in each third, fifth,
and seventh section per treatment group are represented in Table 4. There was no
significant difference when mean third sections were compared between the saline,
meloxicam and buprenorphine treatment groups (One-Way ANOVA F(2,22)= 0.291, p=
0.827). Results indicated no significant difference when comparing mean fifth ovary
section total number of junctions means across treatment groups (One-Way ANOVA
F(2,22)= 9.12, p= 0.371). Results comparing mean seventh polar ovary sections across
treatment groups demonstrated no significant results (One-Way ANOVA F(2,22)= 4.623,
p= 0.771).
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Table 4. Mean and Standard Deviations (SD) for the average total number of junctions
per vessel per treatment group. Each mean represents an average of the means for each
ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9).

Treatment

Total Number of
Junctions per Third
Section (54 µm)

Total Number of
Junctions per Fifth
Section (90 µm)

Total Number of
Junctions per
Seventh Section
(126 µm)
Mean
SD

Mean

SD

Mean

SD

Saline

10239.3

5153.1

15204.6

5994.1

22924.3

4096.9

Meloxicam

11263.5

2752.9

18996.3

5744.2

29125.4

7560.2

Buprenorphine

9920.8

5948.8

11351.0

3757.8

20104.6

4060.3

The percent vessel density means from the third, fifth, and seventh 18 µm
representative sections taken from each ovary pole were averaged and means per
treatment group were compared. One-Way ANOVA was used to analyze the mean
percent vessel density from each polar third section resulting in no significant difference
between the saline treatment group (M= 19.86%, n= 7, SD= 9.34), the meloxicam
treatment group (M= 20.28%, n= 9, SD= 5.12), and the buprenorphine treatment group
(M= 21.79%, n= 9, SD= 7.59) (One-Way ANOVA F(2,22)= 0.158, p= 0.855). OneWay ANOVA was used to compare the percent vessel density mean between each fifth
ovary section from opposite poles per ovary between the saline treatment group (M=
21.61%, n= 7, SD= 7.51), the meloxicam treatment group (M= 32.74%, n= 9, SD=
11.57), and the buprenorphine treatment group (M= 18.41%, n= 9, SD= 5.33). Results
showed a significant difference in the mean percent vessel density across the three
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treatment groups (F(2, 22)= 6.738, p= 0.005, Figure 10). Post-hoc Tukey’s HSD showed
a significant difference between the saline and meloxicam treatment groups (p= 0.045)
and between the meloxicam and buprenorphine treatment groups (p= 0.005). Percent
vessel density from each polar seventh section was also averaged. Results demonstrated
no significant difference between the saline treatment group (M= 28.54%, n= 7, SD=
7.09), the meloxicam treatment group (M= 30.69%, n= 9, SD= 8.49), and the
buprenorphine treatment group (M= 31.65%, n= 9, SD= 6.02) (One-Way ANOVA
F(2,22)= 0.263, p= 0.108). The averaged means and the standard deviations for the
mean percent vessel density in each third, fifth, and seventh section per treatment group
are represented in Table 5.
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Figure 10. Mean percent vessel density determined by averaging the means from polar
fifth sections (approximately 90 µm from the ovary surface) within each treatment group
(n= 25). Saline (M= 21.61%, n= 7, SD= 7.51), meloxicam (M= 32.74%, n= 9, SD=
11.57), buprenorphine (M= 18.41%, n= 9, SD= 5.3). Single asterisks [*] represent a
significant difference between saline and meloxicam (One-Way ANOVA F(2, 22)= 6.738,
p= 0.005). Double asterisks [**] represent a significant difference between meloxicam
and buprenorphine (One-Way ANOVA p= 0.005). Error bars represent 95% confidence
intervals.

Table 5. Mean and Standard Deviations (SD) for the percent vessel density [skeletonized
area (µm) /section area (µm) x 100] per third, fifth, and seventh opposite polar sections
per ovary. Each mean represents an average of the means for each appropriate section
per ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9).
Single asterisks [*] represent significance p= 0.01-0.05. Double asterisks [**] represent
significance p< 0.01.
Treatment

Third Section (54 µm)
Percent Vessel
Density
Mean
SD

Fifth Section (90 µm)
Percent Vessel
Density
Mean
SD

Seventh Section
(126 µm) Percent
Vessel Density
Mean
SD

Saline

19.86

9.34

21.61*

7.51

28.54

7.09

Meloxicam

20.28

5.12

32.74*;**

11.57

30.69

8.49

Buprenorphine

21.79

7.59

18.41**

5.3

31.65

6.02

Vessel Branch and Junction Analysis
The number of branches on each vessel per section were averaged and each
individual section mean was averaged to obtain an average branches per vessel mean for
each ovary. Each ovary mean was averaged per treatment group and compared using a
One-Way ANOVA. Results showed there was no significant difference in the average
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number of branches per vessel means between the saline treatment group (M= 5.541
branches, n= 7, SD= 0.8842), the meloxicam treatment group (M= 4.913 branches, n= 9,
SD= 0.6582), and the buprenorphine treatment group (M= 5.537 branches, n= 9, SD=
0.9783) (One-Way ANOVA F(2, 22)= 1.566, p= 0.231, Figure 11). Post-hoc Tukey’s
HSD comparisons also did not show any significant differences between the treatment
groups (p= 0.325, p= 1.000, p= 0.283). The average number of branches per vessel
means and standard deviations (SD) per treatment group are represented in Table 6.

Mean Number of Branches (Vessel)
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Figure 11. Mean average number of branches per vessel determined by averaging the
mean number of branches per vessel from each ovary within each treatment group (n=
25). Saline (M= 5.541 branches, n= 7, SD= 0.8842), meloxicam (M= 4.913 branches, n=
9, SD= 0.6582), buprenorphine (M= 5.537, n= 9, SD= 0.9783). Error bars represent 95%
confidence intervals.
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Table 6. Mean and Standard Deviations (SD) for the average total number of branches
per vessel per treatment group. Each mean represents an average of the means for each
ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9), buprenorphine (n= 9).
Treatment

Average Number of
Branches per vessel
Mean
SD

Average Number of
Junctions per vessel
Mean
SD

Saline

5.541

0.8842

2.491

0.4776

Meloxicam

4.913

0.6582

2.134

0.3664

Buprenorphine

5.537

0.9783

2.491

0.538

The number of vessel and branch junction points for each vessel per section was
averaged and each individual section mean was averaged to obtain an average number of
junctions per vessel mean for each ovary. Each ovary mean was averaged per treatment
group and the means compared using a One-Way ANOVA. Results showed there was no
significant difference in the total number of junctions per vessel means between the
saline treatment group (M= 2.491 junctions, n= 7, SD= 0.4776), the meloxicam
treatment group (M= 2.134 junctions, n= 9, SD= 0.3664), and the buprenorphine
treatment group (M= 2.491 junctions, n= 9, SD= 0.538) (One-Way ANOVA F(2, 22)=
1.691, p= 0.207, Figure 12). Post-hoc Tukey’s HSD pairwise comparisons also did not
show any significant differences between the treatment groups (p= 0.301, p= 1.000, p=
0.256). The number of junctions per vessel means and standard deviations per treatment
group are represented in Table 6.
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Mean Number of Junctions (Vessel)
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Figure 12. Mean average number of junctions per vessel determined by averaging the
means from each ovary within each treatment group (n= 25). Saline (M= 2.491 junctions,
n= 7, SD= 0.4776), meloxicam (M= 2.134 junctions, n= 9, SD= 0.3664), buprenorphine
(M= 2.491 junctions, n= 9, SD= 0.538). Error bars represent 95% confidence intervals.

All vessel lengths (µm) per ovary section image were counted and a mean vessel
length per image was calculated. Each image mean vessel length was averaged to find
the mean vessel length per ovary per treatment group. The average vessel length (µm)
means and standard deviations per treatment group are represented in Table 7. The
average vessel length per treatment group resulted in an average vessel length of 1.973
µm for the saline treatment group (n= 7, SD= 0.3004), 1.752 µm for the meloxicam
treatment group (n= 9, SD= 0.5165), and 2.095 µm for the buprenorphine treatment
group (n= 9, SD= 0.5282). Results of a One-Way ANOVA comparing vessel lengths
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(µm) across treatment groups showed no significant differences (F(2, 22)= 1.217, p=
0.315, Figure 13).

Table 7. Means and Standard Deviations (SD) for the average vessel length (µm) per
ovary, third, fifth and seventh sections averaged per treatment group. Each mean
represents an average of the means for each ovary (n= 25) per treatment. Saline (n= 7),
meloxicam (n= 9), buprenorphine (n= 9). Single asterisks [*] represent significance p=
0.01-0.05.
Average Vessel
Length (µm) per
Ovary
Mean
SD

Average Vessel
Length (µm) per
Third Section
Mean
SD

Saline

1.973

0.3004

2.101

1.117

2.1236*

0.1936

1.925

0.4923

Meloxicam

1.752

0.5165

1.833

0.5511

3.4254*

1.1154

1.756

0.6102

Buprenorphine

2.095

0.5282

2.362

0.6328

1.9908*

0.5834

2.063

0.6889

Treatment

Average Vessel
Length (µm) per
Fifth Section
Mean
SD

Average Vessel
Length (µm) per
Seventh Section
Mean
SD
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Figure 13. Mean vessel length (µm) per ovary per treatment determined by averaging the
means from each ovary within each treatment group (n= 25). Saline (M= 1.973 µm, n= 7,
SD= 0.3004), meloxicam (M= 1.752 µm, n= 9, SD= 0.5165), buprenorphine (M= 2.095
µm, n= 9, SD= 0.5282). Error bars represent 95% confidence intervals.

The mean vessel length (µm) per third, fifth, and seventh 18 µm sections were
averaged and means per treatment group were compared. The average vessel length
(µm) means and standard deviations for third, fifth, and seventh ovary sections per
treatment group are represented in Table 7. A Kruskal-Wallis ANOVA was used for
section mean vessel length (µm) comparisons since the data violated the assumptions of
homogeneity of variance for a One-Way ANOVA. No significant difference in the mean
vessel length (µm) was shown when each polar third section mean was compared
between treatment groups (Kruskal-Wallis ANOVA: F(2,22)= 1.059, p= 0.364). When
comparing the mean vessel length (µm) per fifth ovary section from opposite poles per
ovary, Kruskal-Wallis ANOVA results indicated a significant difference in between the
saline treatment group (n= 7, SD= 0.1936), the meloxicam treatment group (n= 9, SD=
1.1156), and the buprenorphine treatment group (n= 9, SD= 1.991) (F(2, 22)= 8.424, p=
0.015). Mean vessel length (µm) from each polar seventh section was also compared
across treatment groups with no significant results (Kruskal-Wallis ANOVA F(2,22)=
5.143, p= 0.277).
In addition, all branch lengths (µm) per ovary section image were counted and a
mean branch length per image was calculated. Each image mean branch length was
averaged to find the mean branch length per ovary per treatment group. The average
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branch length (µm) means and standard deviations per treatment group are represented in
Table 8. The average of branch length (µm) per treatment group resulted in an average
branch length of 0.431 µm in the saline treatment group (n= 7, SD= 0.0721), 0.4176 µm
in the meloxicam treatment group (n= 9, SD= 0.1248), and 0.4433 µm in the
buprenorphine treatment group (n= 9, SD= 0.0914). One-Way ANOVA analysis
comparing the average branch lengths between treatment groups did not show any
significant differences across the three groups (F(2,22)= 0.147, p= 0.864, Figure 14.)

Table 8. Means and Standard Deviations (SD) for the average branch length (µm) per
ovary, third, fifth, and seventh sections averaged per treatment group. Each mean
represents an average of the means for each ovary (n= 25) per treatment. Saline (n= 7),
meloxicam (n= 9), buprenorphine (n= 9).
Average Branch
Length (µm) per
Ovary
Mean
SD

Average Branch
Length (µm) per
Third Section
Mean
SD

Average Branch
Length (µm) per
Fifth Section
Mean
SD

Average Branch
Length (µm) per
Seventh Section
Mean
SD

Saline

0.4310

0.0721

0.4922

0.2006

0.4622

0.0653

0.4405

0.1138

Meloxicam

0.4176

0.1248

0.4284

0.1392

0.4198

0.2621

0.4227

0.1456

Buprenorphine

0.4433

0.0914

0.4837

0.0697

0.4732

0.1033

0.4650

0.1069

Treatment
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Figure 14. Mean branch length (µm) per ovary per treatment determined by averaging
the means from each ovary within each treatment group (n= 25). Saline (M= .431 µm,
n= 7, SD= 0.0721), meloxicam (M= 0.4176 µm, n= 9, SD= 0.1248), buprenorphine (M=
0.4433 µm, n= 9, SD= 0.0914). Error bars represent 95% confidence intervals.

Mean branch lengths (µm) per third, fifth, and seventh 18 µm sections were
averaged and means per treatment group were compared using a Kruskal-Wallis ANOVA.
The average branch length (µm) means and standard deviations per treatment group are
represented in Table 8. No significant difference in the mean vessel length (µm) was
shown when each polar third section mean was compared between treatment groups
(Kruskal-Wallis ANOVA: F(2,22)= 0.872, p= 0.183). Mean branch length (µm) from
each polar fifth section was compared across treatment groups with no significant results
(Kruskal-Wallis ANOVA: F(2,22)= 5.143, p= 0.277) and the mean branch length (µm)

	
  
61	
  

	
  

comparison of seventh section depths across treatment groups were not significant
(Kruskal-Wallis ANOVA: F(2,22)= 9.33, p= 0.405).

Ovary Area Analysis
There was no significant difference when the cross-sectional area of the
individual third, fifth, and seventh 18 µm sections were averaged and compared across
treatment groups using One-Way ANOVAs. The average section area (mm2) means and
standard deviations for third, fifth, and seventh ovary sections per treatment group are
represented in Table 9. The average third section cross-sectional area of the saline
treatment group was 0.221 mm2 (n= 7, SD= 0.131), the meloxicam treatment group was
0.219 mm2 (n= 9, SD= 0.113), and the buprenorphine group was 0.235 mm2 (n= 9, SD=
0.162). Results demonstrated no significant difference between third section crosssectional areas when compared between treatment groups (F(2,22)= 0.036, p= 0.965).
The average fifth section cross-sectional area of the saline treatment group was 0.449
mm2 (n= 7, SD= 0.165), the meloxicam treatment group was 0.599 mm2 (n= 9, SD=
0.269), and the buprenorphine group was 0.471 mm2 (n= 9, SD= 0.206). Results
demonstrated no significant difference between fifth section cross-sectional areas across
treatment groups (F(2,22)= 1.145, p= 0.337). The average seventh section crosssectional area of the saline treatment group was 0.674 mm2 (n= 7, SD= 0.304), the
meloxicam treatment group was 0.752 mm2 (n= 9, SD= 0.411), and the buprenorphine
group was 0.645 mm2 (n= 9, SD= 0.253). Results demonstrated no significant difference
between seventh section cross-sectional areas across treatment groups (F(2,22)= 1.145,
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p= 0.337). In addition, the third, fifth, and seventh cross-sectional area means were
averaged together to give a mean surface area per ovary. One-Way ANOVA was used to
compare ovary area means between the saline treatment group (M= 0.448 mm2, n= 7,
SD= 0.141), the meloxicam treatment group (M= 0.445 mm2, n= 9, SD= 0.180), and the
buprenorphine treatment group (M= 0.529 mm2, n= 9, SD= 0.207). Results
demonstrated no significant difference in mean ovary surface areas across treatment
groups (One-Way ANOVA: F(2,22)= 0.608, p= 0.553, Figure 15). The average ovary
surface area (mm2) means and standard deviations per treatment group are represented in
Table 9.

Table 9. Means and Standard Deviations (SD) for the average ovary surface area (mm2),
average third section area (mm2), average fifth section area (mm2), and average seventh
section area (mm2) averaged per treatment group. Each mean represents an average of
the means for each ovary (n= 25) per treatment. Saline (n= 7), meloxicam (n= 9),
buprenorphine (n= 9).
Treatment

Average Ovary
Surface Area (mm2)

Average Third
Section Area
(mm2)
Mean
SD

Average Fifth
Section Area
(mm2)
Mean
SD

Average Seventh
Section Area
(mm2)
Mean
SD

Mean

SD

Saline

0.448

0.141

0.221

0.131

0.449

0.165

0.674

0.304

Meloxicam

0.445

0.180

0.219

0.113

0.599

0.269

0.752

0.411

Buprenorphine

0.529

0.207

0.235

0.162

0.471

0.206

0.645

0.253
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Figure 15. Mean ovary surface area (mm2) per ovary per treatment determined by
averaging the means from each ovary within each treatment group (n= 25). Saline (M=
0.448 mm2, n= 7, SD= 0.141), meloxicam (M= 0.445 mm2, n= 9, SD= 0.180),
buprenorphine (M= 0.529 mm2, n= 9, SD= 0.207). Error bars represent 95% confidence
intervals.
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DISCUSSION
The results of the present study indicate a difference between the mean total
number of vessels per ovary when comparing the saline treatment group to the
meloxicam treatment group and between the meloxicam and buprenorphine treatment
groups. When comparing the mean total number of vessels, mean total branch number,
and mean percent vessel density between each of the treatment groups by ovary section, a
significant difference was found between the fifth (approximately 90 µm from the ovary
surface) sections of the saline and meloxicam treatment groups and the meloxicam and
buprenorphine treatment groups. Between the seventh (approximately 126 µm from the
ovary surface) sections, there was a significant difference in the mean total number of
vessels between the meloxicam and buprenorphine treatment groups only.
In addition, a significant difference was found when comparing the seventh section total
number of branches and total number of junctions per ovary means between the
meloxicam treatment group and the buprenorphine treatment group.
When using a murine model to evaluate angiogenesis following ovarian
allotransplantation, the use of an analgesic such as meloxicam or buprenorphine is
recommended to reduce deleterious post-operative complications caused by pain and
inflammation. Our results indicate that meloxicam would be the preferential analgesic
for post-ovarian transplantation pain management due to the significant increase in total
number of vessels present per ovary and in the total number of vessels present at a depth
of 72-90 µm when compared to the saline treatment control group. The significant
number of vessels observed with post-operative meloxicam administration suggests that
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an increased amount of angiogenesis occurred after ovary allotransplantation reducing the
possibility of altered blood flow to the donor ovary and increasing chances of recovering
normal estrus cyclicity while providing adequate analgesia.
This is the first known study to specifically evaluate the effects of analgesics
such as buprenorphine and meloxicam on post-operative ovary allotransplantation
angiogenesis in aged female mice; our results can be compared to previous research that
examined the effects of these drug’s parent groups, morphine and COX-2 inhibitors, on
angiogenesis in other tissue types. When comparing the results of the present study with
the aforementioned type of previous angiogenesis research, the significant findings are
markedly different.
While the present study demonstrates no significant difference in the total number
of vessels between the buprenorphine treatment group and the saline treatment control
group, several studies looking at the effects of opioids on angiogenesis demonstrated
significant contradicting increases and decreases in new vessel formation (Lam, 2008;
Poonawala, 2005). When comparing research methodologies, it is possible that
differences in tissue staining, vessel analysis software, or drug dosage could have caused
the variations in results. For example, a study by Lam et al (2008) evaluating the effects
of high-dose morphine on angiogenesis in mice showed a significant decrease in
angiogenesis and delayed wound healing with the IP administration of a 20 mg/kg⋅day
morphine dose given for 14 consecutive days compared to the IP administration of a
similar dose of saline control for 14 days. The morphine dosing guidelines chosen by
Lam et al were based on previous mouse and rat models of morphine dependence and
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demonstrated continual high morphine and morphine metabolite serum concentrations
with 20 mg/kg⋅day dosing. Comparatively, the present study administered the
veterinarian recommended dose for adequate post-operative pain relief which consisted
of a 0.05 mg/kg dose of buprenorphine every 12 hours for 48 consecutive hours resulting
in a significant decrease in the number of vessels in the saline and buprenorphine
treatment groups compared to the meloxicam treatment group. In addition, both the
present study and the study by Lam et al used CD31-antibody stained tissue sections for
identification of vascularization for subsequent angiogenesis quantification. Although
identical CD31-antibody immunohistochemistry (IHC) was used in both studies, Lam et
al employed a subcutaneous Matrigel (extracellular environment simulation) mesh to
facilitate new microvessel formations instead of organ transplantation as was done
presently.
In a contradictory study by Poonawala et al (2005), high-dose morphine
administration resulted in a significant increase in angiogenesis and reduction in healing
time when administered topically to excisional and incisional wounds. To identify
angiogenesis, tissue samples used by Poonawala et al were fluorescently 4’-6’-diamino2-phenylindole (DAPI) stained and vessel quantitation was done using Adobe Photoshop
software whereas the present study used a DAB stain and Image J software for
vascularization analysis. Differences in the accuracy of the software algorithms used for
vessel identification could account for the decrease in vessel formation in the saline and
buprenorphine groups compared to the meloxicam group seen in the present study
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compared to the increase in angiogenesis after topical morphine treatment seen by
Poonawala et al.
The present results show a significant increase in angiogenesis in the meloxicam
treatment group compared to saline control contradicting previous research that
overwhelmingly demonstrated a statistically significant decrease in angiogenesis after
treatment with specific COX-2 inhibitors (Howe, 2005; Jones, 1999; Schmassmann,
1998; Xin, 2007). It is possible that differences in drug dosage, type of tissue analyzed,
and type of selective COX-2 inhibitor could be responsible for the dissimilarities in
research results between studies. For example, Leahy et al (2002) observed a significant
decrease in angiogenesis after performing the same IHC CD31-antibody staining/DAB
chromogen protocol for vessel identification as was done in the present study. Although
the method of vessel identification was similar, Leahy et al used celecoxib in a rat cornea
model compared to meloxicam in a murine ovarian tissue transplant model as done
presently. The main difference between the selective COX- 2 inhibitor celecoxib and the
selective COX-2 inhibitor meloxicam is the addition of a side-chain sulfonamide group.
This allows celecoxib’s large molecular structure to inhibit enzymatic activity by strongly
binding to the central active site on the COX-2 enzyme compared to the top of the active
site where meloxicam binds causing full potency (Tmax) to be reached within 2 hours. In
addition, celecoxib is exceedingly bioavailable through oral routes with minimal
gastrointestinal effects at high doses (Penning, 1997). Although celecoxib may
effectively ameliorate pain in patients with osteoarthritis, rheumatoid arthritis, and spinal
fusion, the addition of the sulfonamide side-chain is more likely to cause systemic and
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tissue reactions and increases risk of infarction. When comparing animal models, the rat
cornea model is used due to excellent visualization of new vessel formation but
angiogenic and mitogenic stimulation via VEGF or bFGF are usually exogenously
administered. In the murine ovarian allotransplantation model, hypoxia and
inflammation in the transplanted tissue stimulate an endogenous cascade of angiogenic
factors such as VEGF, bFGF, COX-2, and PGE2 leading to rapid vessel formation. With
many factors acting in response to the ovary transplantation, dissimilarities in observed
results between the present study and Leahy et al could emanate from the differences
between endogenous versus exogenous angiogenesis stimulation. In a completely in vitro
study, Jones et al (1999) used rat aortic endothelial cells and HUVECs in a Matrigel mesh
culture with the sulfonamide-containing selective COX-2 inhibitor NS-398 resulting in a
statistically significant decrease in microvessel formation compared to the present in vivo
study demonstrating an increase in new vessel formation in transplanted murine ovarian
tissue. In Jones et al (1999), the Matrigel mesh was used since it provides an
environment that mimics a normal in vivo extracellular environment for cultured rat
aortic endothelial cells or HUVECs which will subsequently form capillary-like web
structures on the mesh by releasing endogenous angiogenesis stimulating growth factors
such as VEGF and bFGF. The secretion of these cellular mitogens on the mesh will
allow the cultured cells to anastomose, creating a network of endothelial cells that
represent normal endogenous angiogenic processes. To observe alterations in
angiogenesis using this model, 25 to 100 µM of the selective COX- inhibitor NS-398 was
added to the cell culture Matrigel mesh and the formation of capillary structures was
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photographed after incubation. When compared to the present study, contradictions in
observed results could be from the significantly different tissue model used between
studies. Although the Matrigel mesh extracellular environment provides excellent
observation of capillary structure formation, the use of ovary transplantation in the
present study exposes the transplanted ovarian tissue to hypoxia induced growth factor
secretion, inflammatory cytokine cascade, and invading leukocytes which could have
both acute and long-term angiogenic effects compared to the swift response of the rat
aortic cells and HUVECs on the Matrigel mesh environment. The mechanism of action
differences between selective COX-2 inhibitors as well as differences between chosen
tissue models could have influenced observed results between the increase in vessel
formation in the meloxicam-treated mice in the present study and the decrease in
angiogenesis in the NS-398 treated cell culture in Jones et al.
In the normal female murine reproductive cycle, maturation of primordial follicles
into Graafian follicles requires the formation of superficial vascular networks that
surround the developing follicle in order to deliver necessary nutrients and remove
metabolic wastes (Boron & Boulpaep, 2008). Previous studies observed a significant
decrease in angiogenesis after both morphine and meloxicam administration using aortic,
intestinal, and umbilical vein cell cultures on Matrigel mesh. Although these cell cultures
are fantastic for studying cellular responses to hypoxia and inflammation, their
representative tissues are not normally subjected to an upregulated prostaglandin
production via COX-2 inflammation response and MAP kinase (MAPK) signaling that is
ongoing in normal ovarian folliculogenesis (Kuwano, 2004). COX-2 has been identified
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on outer ovarian surface epithelium and studies have shown that increases in both COX-2
activity and a product of COX-2 prostanoid production, prostaglandin E2 (PGE2), can
increase angiogenesis in ovarian follicles by stimulating VEGF production in the luteal
phase ovary during the menstrual cycle by signaling the MAPK pathway for angiogenesis
at the transcription level (Ferrara, 1998; Li, 1994; Stavreus-Evers, 2005; Xin, 2007). In
addition to normal physiological COX-2 enzymatic activity, studies have shown that
normal folliculogenesis can be considered an inflammatory event with increased
production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), a macrophage
derived cytokine, that participates in follicular rupture and stimulates VEGF and
interleukin-6 (IL-6) from ovarian stromal cells (Brannstrom, 1993; Lebovic, 2000). The
synthesis and expression of IL-1β and its receptor have been identified in human ovarian
granulosa cells and increased IL-1β can induce ovulation in rat and rabbit ovaries in vivo
(Brannstrom 1993; Peterson, 1993; Takehara, 1994). In the present study, male mice
were housed in adjacent cages to ensure proper estrous cycling (Whitten, 1956) while
females housed together normally tend to have synchronized estrus cycles. This suggests
that the pre-operative levels of IL-1β, COX-2, PGE2, VEGF, and MAPK activated
mitogenesis could have been at normal physiological levels before ovary
allotransplantation and analgesia administration. Due to the normal ongoing activity of
these angiogenic factors, veterinary recommended pain management dosages for
buprenorphine and meloxicam could fail to inhibit neovascularization and vascular bed
remodeling in the newly transplanted ovaries.

	
  
71	
  

	
  

Post-transplantation, the normal inflammatory response could have increased
physiological levels of COX-2, PGE2 production, and IL-1β, which in turn stimulated
increased VEGF and ultimately MAP kinase signaling in multiple areas such as outer
epidermis, abdominal wall musculature, ovarian bursa, donor ovary, and around the
foreign suture material. After the post-operative administration of meloxicam, selective
COX-2 inhibition should have swiftly decreased the production of PGE2 and subsequent
production of VEGF, ubiquitously reducing MAP kinase signaling and the production of
secreted angiogenic factors leading to the inhibition of angiogenesis. Contradictorily, our
data demonstrated a significant increase in angiogenesis after post-operative treatment
with meloxicam, suggesting the pro-angiogenic effects of other inflammatory cytokines
such as IL-1β could have amplified the production of VEGF in the absence of COX-2
activity. In previous studies, IL-1β has been shown to rapidly stimulate angiogenesis in
mouse corneas in vivo and in cell culture in vitro both independently and by enhancing
COX-2 expression resulting in increased PGE2 production, stimulating VEGF and
subsequent MAPK vascular endothelial cell mitogenesis (Kirtikara, 2000; Kuwano,
2004). Although some selective COX-2 inhibitors have been shown to inhibit IL-1β
activation of VEGF, the possibility of elevated levels of COX-2, PGE2, IL-1β, and VEGF
present in normal estrus cycling in addition to the standard post-operative inflammatory
response elevation of the same factors may explain the significant increase in the
meloxicam group vessel formation and no significant decrease in the buprenorphine
group vessel formation if the veterinarian recommended meloxicam doses were
insufficient to inhibit a significant amount of angiogenic signaling (Kuwano, 2004).
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Compared to similar studies looking at selective COX-2 inhibition of angiogenesis, IP
administered doses ranged from 20 mg/kg⋅day to 5 mg/kg⋅day while a 5 mg/kg dose was
given twice daily to the animals in the present study. Differences in administration time
could also have altered inhibition of angiogenesis since Lam et al (2008) administered
morphine regularly for 14 days compared with the 48 hours as done in the present study.
Although the increase in cytokine IL-1β and subsequent VEGF stimulation or short
duration of standard meloxicam post-operative dosing could explain the difference in
results between the meloxicam and buprenorphine treatment groups, they fail to
adequately explain the lack of elevated angiogenesis in the saline treatment group. This
result could be explained by evaluating the relationship between meloxicam induced
COX-2 inhibition and the anterior pituitary secreted gonadotropins follicle-stimulating
hormone (FSH) and luteinizing hormone (LH).
In animals with normal, physiologically attached ovaries, sex hormone regulation
is controlled through secretion of the neurohormone gonadotropin-releasing hormone
(GnRH) by the hypothalamus. The secreted GnRH travels through the hypophyseal
portal system and stimulates the gonadotrophs within the anterior pituitary gland to
secrete FSH and LH into peripheral circulation. Anterior pituitary released LH binds to
thecal cells in the ovary, stimulating the production of androgens. In granulosa cells,
FSH binds and stimulates the estrogen synthetase conversion of androgens into estrogens
during FSH-stimulated folliculogenesis. Increased estrogens released into circulation
from the maturing ovarian follicle inhibit additional secretion of GnRH through the longloop feedback mechanism of sex hormone regulation until estrogen levels begin to
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decline. During the murine ovary allotransplantation, the new ovary is placed into the
host bursa without reattaching either the blood vessels of the inner mesothelium lining or
the ovarian artery and ovarian vein at the hilum. Removal of direct vascular
communication with the ovary causes a reduction in delivered LH and FSH resulting in a
decrease in the systemic circulating steroid hormone estrogen supplied by the ovary
during the murine estrous cycle. In response to diminishing circulating estrogen, GnRH
stimulates the secretion of FSH and LH due to the removal of estrogen’s negative
feedback. In a previous study by Dissen et al (1994), rat ovaries were removed and
autotransplanted adjacent to a jugular vein. Within 48 hours, post-operative increases in
both FSH and LH could be detected in response to decreasing estrogen levels. In
addition, ovarian VEGF and transforming growth factor β (TGF-β) mRNA levels
increased within 24 hours. Using FSH and LH antagonists, Dissen et al determined that
angiogenic factors VEGF and TGF-β are upregulated when gonadotropin secretion is
elevated. In a separate study by Davis et al (1999), mice with a COX-2 null (-/-)
mutation exhibited higher levels of pituitary FSH and LH when compared to wildtype
(COX-2 +/+) mice. When comparing Davis et al and Dissen et al with the present study,
the increased number of vessels seen in the meloxicam treatment group may be due to
elevated levels of gonadotropins associated with both COX-2 enzymatic activity
inhibition and a post-operative ovary transplantation gonadotropin surge.
While this is the first known study to look at the effects of post-operative
meloxicam administration on vessel formation after ovary allotransplantation, our results
indicating an increase in angiogenesis could also be a response to the aged state of the
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recipient mice, restrictive or regulating effects of the murine ovarian bursa, or a possible
cooperative response due to an unknown relationship between the ovary and meloxicam.
Other factors that could have affected results include the smaller number of saline
treatment control animals (n= 7) as compared to the buprenorphine treatment group (n=
9) and the meloxicam treatment group (n= 9). This inequality could have accounted for
the lack of significant decrease in angiogenesis between saline and buprenorphine groups
and the significant increase in angiogenesis between the meloxicam and the saline control
group demonstrated in similar research (Balasubramanian, 2001; Lam, 2008; Roy, 2003).
The large calculated confidence intervals also indicate a relatively small number of
animals per treatment group which could have influenced the results due to an increase in
Type 1 error. Counting older vessels as new vessel formations or counting the same
vessel twice could also have influenced the total number of vessels when comparing the
meloxicam and buprenorphine treatment groups.
Several limitations could have impacted the results of the present study. When
looking at surface vascularization of a semi-transparent, round, three-dimensional tissue
specimen such as an ovary, it can be difficult to differentiate between true surface vessel
formations and previously established vessels relatively close to the surface. For the
present study, the ovaries were sectioned to evaluate surface vascularization by analyzing
vessel formations from third, fifth, and seventh polar representative layers, but future
studies might benefit from in vivo tissue perfusion of fluorescent or colored dye
immediately before sacrifice to evaluate all superficial vessel formations and to visually
confirm true surface vascularization from established vessel formations directly below
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the surface that could falsely increase the number of counted vessels. In the present study,
an effort was made to correctly calculate the total number of vessels and all vessel
components within each third, fifth, and seventh polar opposite ovary sections and
computer software was employed to remove counting bias and process each image
swiftly and uniformly as was done in previous studies (Chantrain, 2003; Doukas, 2006;
Seaman, 2011; Vickerman, 2009). In studies that did not use computer automated vessel
analysis but also used CD31 cell surface antigen to identify tissue microvessels, other
methods of vessel counting were utilized such as the Chalkley count or taking random
“hotspot” counts (Fox, 1995; Vermeulen, 1996; Vermeulen, 2002). Future studies could
benefit from a computer automated count and a simultaneous Chalkley count comparison
to confirm microvessel density analysis or a separate comparison using a different
software program such as MetaMorph, VESGEN 2D, or Adobe Photoshop. Additionally,
several studies that used CD31 antibody to identify vascular endothelial cells used a
hematoxylin or methyl green counterstain which could be helpful to confirm
identification of CD31-antibody identified, DAB-stained vascular endothelial cells and
should be considered for use in future studies looking at endothelial cell identification
(Jennings, 2012; Li, 2005).
The effects of analgesia on post-operative transplantation angiogenesis can
benefit from further evaluation and separate corroborative studies. The results of the
present study can be verified by performing comparable investigations that employ
alternate vessel quantification methods and novel superficial vessel identification
techniques while utilizing larger sample sizes. Successful transplantation relies on
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adequate angiogenesis for swift perfusion of new tissues while sufficient post-operative
pain management can benefit the animal and research results by limiting discomfort.
While the current study supports the use of meloxicam as a potent analgesic that would
not negatively affect transplant success, further research and separate independent
verification is warranted before adding meloxicam to future murine ovarian
allotransplantation protocols.
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